{"meta":{"query_hash":"d78694197d76","filters":{"venue":"Clinical Neuropharmacology"},"cohort_total":70,"direct_labels_cover":0,"predictions_cover":70,"exported":70,"export_cap":100000,"truncated":false,"label_status":"direct model label, unvalidated","prediction_status":"machine_predicted_unvalidated (Codex and Gemma teacher distillation)","score_status":"score_only:v0-immature-baseline","snapshot":{"source":"OpenAlex, pinned release, all 482 partitions","release":"2026-06-24","frame_built":"2026-07-12"},"permalink":"https://metacan.xera.ac/q/d78694197d76","api":"https://metacan.xera.ac/api/v1/cohort?venue=Clinical+Neuropharmacology"},"results":[{"id":"W117490009","doi":"10.1097/wnf.0b013e3181c46f48","title":"A Prospective, Randomized, Double-Blind Study Comparing the Efficacy and Safety of Type A Botulinum Toxins Botox and Prosigne in the Treatment of Cervical Dystonia","year":2010,"lang":"en","type":"article","venue":"Clinical Neuropharmacology","topic":"Botulinum Toxin and Related Neurological Disorders","field":"Medicine","cited_by":74,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Cervical dystonia; Spasmodic Torticollis; Medicine; Tolerability; Randomized controlled trial; Botulinum toxin; Dystonia; Quality of life (healthcare); Adverse effect; Anesthesia; Torticollis; Rating scale; Surgery; Internal medicine; Psychology","score_opus":0.06563286935701265,"score_gpt":0.396070542860635,"score_spread":0.3304376735036223,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W117490009","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98993045,0.00033361276,0.0000013705885,0.0031031475,0.00039024508,0.005902119,0.0000016798774,0.000018925368,0.000318426],"genre_scores_gemma":[0.9967974,0.0021979627,0.000031104704,0.0007610883,0.00009107511,0.00006970194,0.00000124313,0.000015892769,0.000034569202],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9970823,0.0010586443,0.0010058781,0.00044852396,0.00016809172,0.00023659674],"domain_scores_gemma":[0.9946582,0.0046235565,0.00022546014,0.00029889427,0.00007554434,0.00011837369],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010602043,0.00021173386,0.0011491909,0.00006173794,0.00008339952,0.000008991455,0.00017862374,0.00021296323,0.000044940272],"category_scores_gemma":[0.00044470595,0.00009716884,0.00014907274,0.0003040482,0.0015728904,0.000020608903,0.000090865666,0.0009884211,0.0000030593117],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7108954,0.013533511,0.26368263,0.0000465753,0.00037555242,0.00017857458,0.0014794718,0.000014437193,0.007914523,0.00040731224,0.000027366952,0.0014446562],"study_design_scores_gemma":[0.47869805,0.009367881,0.50955313,0.000009687966,0.00069355627,0.000070278984,0.000094565556,0.0007579756,0.0002183047,0.00008060755,0.0003712583,0.00008473354],"about_ca_topic_score_codex":0.0000249851,"about_ca_topic_score_gemma":0.000035088327,"teacher_disagreement_score":0.2458705,"about_ca_system_score_codex":0.0000062564054,"about_ca_system_score_gemma":0.00005471292,"threshold_uncertainty_score":0.57953805},"labels":[],"label_agreement":null},{"id":"W1824305151","doi":"10.1097/wnf.0b013e318059be76","title":"Add-on Therapy With Acetylcholinesterase Inhibitors for Memory Dysfunction in Schizophrenia","year":2007,"lang":"en","type":"review","venue":"Clinical Neuropharmacology","topic":"Schizophrenia research and treatment","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Donepezil; Rivastigmine; Neurocognitive; Schizophrenia (object-oriented programming); Galantamine; Randomized controlled trial; Placebo; Memory impairment; Psychology; Medicine; Verbal memory; Meta-analysis; Clinical trial; Cognition; Dementia; Psychiatry; Internal medicine","score_opus":0.20501452474498705,"score_gpt":0.4969339128382372,"score_spread":0.29191938809325013,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1824305151","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.046160698,0.9436309,0.000008519192,0.0004282095,0.0022507622,0.0071827713,0.000061552564,0.0001308928,0.0001457303],"genre_scores_gemma":[0.00045732837,0.99223053,0.0005677602,0.0020643831,0.0028538087,0.0010287627,0.00022271862,0.0001804865,0.000394225],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9952108,0.0007959284,0.001601456,0.001245468,0.00037546875,0.00077082566],"domain_scores_gemma":[0.9932404,0.0049764635,0.00042098982,0.0005816486,0.00016195464,0.00061853527],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0010099045,0.00071557076,0.0028102195,0.00073182076,0.00008234284,0.000021977317,0.00024963927,0.0007104515,0.00020124792],"category_scores_gemma":[0.00063155434,0.00045236404,0.00091344205,0.00065442646,0.0003166654,0.00005228204,0.00007143586,0.0021856208,0.0002510905],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06870836,0.0020207218,0.00008631773,0.0017136413,0.00042027707,0.001867434,0.0000029694565,8.7544265e-7,0.0000045559273,0.00001587566,0.0025397441,0.9226192],"study_design_scores_gemma":[0.049155526,0.01118527,0.0006605237,0.0027668213,0.0010527299,0.00033571105,0.0000028332283,0.000009388729,0.000037789938,0.000011329095,0.934354,0.00042807983],"about_ca_topic_score_codex":0.0000043848418,"about_ca_topic_score_gemma":0.000019184901,"teacher_disagreement_score":0.93181425,"about_ca_system_score_codex":0.00019499606,"about_ca_system_score_gemma":0.001198976,"threshold_uncertainty_score":0.9997928},"labels":[],"label_agreement":null},{"id":"W1923911528","doi":"10.1097/wnf.0000000000000101","title":"A Comparison of Botox 100 U/mL and Dysport 100 U/mL Using Dose Conversion Ratio 1","year":2015,"lang":"en","type":"article","venue":"Clinical Neuropharmacology","topic":"Botulinum Toxin and Related Neurological Disorders","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Allergan; Ipsen","keywords":"Medicine; Cervical dystonia; Confidence interval; Spasmodic Torticollis; Randomized controlled trial; Anesthesia; Botulinum toxin; Significant difference; Crossover study; Surgery; Torticollis; Internal medicine","score_opus":0.2577468131499699,"score_gpt":0.4951198360469998,"score_spread":0.23737302289702988,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1923911528","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.993999,0.0005167945,0.00004781416,0.0025930398,0.001376281,0.00052683655,0.0000039362726,0.00007906358,0.00085723854],"genre_scores_gemma":[0.99142534,0.0006442618,0.0002431599,0.007190408,0.00017754725,0.0000043457662,0.000008502098,0.00002872529,0.00027771606],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9973868,0.00050183403,0.00102694,0.00052674935,0.00023042403,0.0003272272],"domain_scores_gemma":[0.9979781,0.0007593515,0.0003181845,0.00022485595,0.00015647673,0.00056305114],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00048430523,0.00021364861,0.00090569886,0.000097812546,0.00006573535,0.000006687289,0.00013731456,0.00043913504,0.00032162623],"category_scores_gemma":[0.000715649,0.00016993773,0.00016974691,0.00024606482,0.00082529587,0.000056186425,0.00017423455,0.0009791838,0.00006517799],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014107723,0.006748806,0.7544877,0.00028312104,0.00046226892,0.0023340979,0.00037835917,0.00047305154,0.17665794,0.00019702267,0.035474397,0.008395516],"study_design_scores_gemma":[0.07242793,0.03468389,0.6040995,0.00015027565,0.003616119,0.00091059704,0.0005196109,0.15423231,0.01790951,0.00056315865,0.10956955,0.0013175525],"about_ca_topic_score_codex":0.000010699742,"about_ca_topic_score_gemma":5.866742e-7,"teacher_disagreement_score":0.15874843,"about_ca_system_score_codex":0.000018385042,"about_ca_system_score_gemma":0.00018558417,"threshold_uncertainty_score":0.69298595},"labels":[],"label_agreement":null},{"id":"W1963544666","doi":"10.1097/wnf.0b013e31819a68b5","title":"Effectiveness of Switching to Aripiprazole From Atypical Antipsychotics in Patients With Schizophrenia","year":2009,"lang":"en","type":"article","venue":"Clinical Neuropharmacology","topic":"Schizophrenia research and treatment","field":"Medicine","cited_by":47,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Otsuka Pharmaceutical","keywords":"Aripiprazole; Schizophrenia (object-oriented programming); Positive and Negative Syndrome Scale; Neurocognitive; Wisconsin Card Sorting Test; Psychology; Brief Psychiatric Rating Scale; Akathisia; Rating scale; Scale for the Assessment of Negative Symptoms; Psychiatry; Cognition; Trail Making Test; Global Assessment of Functioning; Clinical psychology; Psychosis; Antipsychotic; Neuropsychology; Developmental psychology","score_opus":0.02359581114582315,"score_gpt":0.3757193929095006,"score_spread":0.3521235817636775,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1963544666","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99789685,0.000032542564,0.000083863015,0.00068199745,0.00031109966,0.00091712346,0.000012197348,0.000030399657,0.000033917197],"genre_scores_gemma":[0.99604064,0.000032409014,0.0028137153,0.0009469368,0.00011223478,0.000011878529,0.000020189369,0.00001880412,0.000003197674],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9977518,0.000532073,0.0005948091,0.00050333433,0.00027074176,0.00034725922],"domain_scores_gemma":[0.99761045,0.0014556902,0.00009237807,0.00029619937,0.0001225293,0.00042277397],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00036617066,0.00018040437,0.00065868965,0.00016030278,0.000028401559,0.0000066944426,0.00015518618,0.00011983668,0.000065180655],"category_scores_gemma":[0.0005730314,0.0001340695,0.0001059797,0.0003478922,0.000083174134,0.0000418175,0.000054080036,0.0006224673,0.00006853711],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.3536862,0.0030789059,0.6198571,0.00001839018,0.0000845039,0.0002851372,0.000007769797,0.00001466752,0.0044746012,0.00008494424,0.000047179572,0.01836061],"study_design_scores_gemma":[0.03214027,0.008193637,0.9571451,0.00010827829,0.000093854076,0.0000029837165,0.0000013318471,0.0000671044,0.0017560598,0.00034902003,0.000038810624,0.000103538965],"about_ca_topic_score_codex":0.000006933682,"about_ca_topic_score_gemma":0.0000048978545,"teacher_disagreement_score":0.33728805,"about_ca_system_score_codex":0.00004056365,"about_ca_system_score_gemma":0.00014295235,"threshold_uncertainty_score":0.54671955},"labels":[],"label_agreement":null},{"id":"W1970671532","doi":"10.1097/00002826-200309000-00004","title":"Poor Tolerability of a Transdermal Nicotine Treatment in Parkinson's Disease","year":2003,"lang":"en","type":"article","venue":"Clinical Neuropharmacology","topic":"Nicotinic Acetylcholine Receptors Study","field":"Biochemistry, Genetics and Molecular Biology","cited_by":25,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôtel-Dieu de Montréal; Hôtel-Dieu de Québec; Université du Québec à Montréal; Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Tolerability; Transdermal; Medicine; Nicotine; Nausea; Vomiting; Adverse effect; Anesthesia; Parkinson's disease; Pharmacology; Internal medicine; Disease","score_opus":0.031157462677720807,"score_gpt":0.36045654070042094,"score_spread":0.32929907802270014,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1970671532","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99737734,0.00046707192,0.000037792706,0.00046252046,0.00069242535,0.000550985,0.000026920443,0.000012558358,0.0003723621],"genre_scores_gemma":[0.9974546,0.0008599519,0.00021880085,0.000949974,0.00019025482,0.00006244132,0.000017426559,0.00002807685,0.00021848168],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99683446,0.0011623045,0.00087609293,0.00067139725,0.00009786889,0.00035788285],"domain_scores_gemma":[0.99888957,0.00025399748,0.000161241,0.00037523208,0.000059765127,0.00026022203],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00048103454,0.00022450609,0.00048887933,0.000042375934,0.000029010464,0.0000032605385,0.00021093336,0.00015793937,0.00020048792],"category_scores_gemma":[0.0008109555,0.00020318083,0.00029681603,0.0001362801,0.00029079014,0.0000030077522,0.00006187346,0.00021139979,0.00001521723],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019431781,0.0061141727,0.79658455,0.0000364483,0.00012230585,0.000021999986,0.000029192415,0.00014627076,0.18891928,0.000064964624,0.0010158821,0.005001778],"study_design_scores_gemma":[0.014895781,0.0044127004,0.21193928,0.000009857089,0.00020868288,0.000017793034,0.000026868913,0.00016776762,0.25145987,0.00004891761,0.516302,0.0005104579],"about_ca_topic_score_codex":0.000008253185,"about_ca_topic_score_gemma":0.000022014083,"teacher_disagreement_score":0.5846453,"about_ca_system_score_codex":0.000020202831,"about_ca_system_score_gemma":0.00025791835,"threshold_uncertainty_score":0.82854736},"labels":[],"label_agreement":null},{"id":"W1977455030","doi":"10.1097/01.wnf.0000220817.94102.95","title":"The Controversy Concerning Plasma Homocysteine in Parkinson Disease Patients Treated with Levodopa Alone or with Entacapone","year":2006,"lang":"en","type":"review","venue":"Clinical Neuropharmacology","topic":"Folate and B Vitamins Research","field":"Medicine","cited_by":38,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre for Movement Disorders","funders":"","keywords":"Entacapone; Levodopa; Catechol-O-methyl transferase; Parkinson's disease; Homocysteine; Hyperhomocysteinemia; Concomitant; Medicine; Plasma homocysteine; Internal medicine; Pharmacology; Endocrinology; Psychology; Disease; Chemistry; Biochemistry; Genotype","score_opus":0.09628879543517495,"score_gpt":0.4267736520732911,"score_spread":0.33048485663811616,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1977455030","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.26435485,0.72874177,8.978929e-7,0.00043066347,0.0004846103,0.0053016236,0.00017133517,0.000103594204,0.00041066334],"genre_scores_gemma":[0.019736629,0.9741244,0.00001579872,0.0005950257,0.0005075251,0.00036127036,0.0003970744,0.00015549429,0.004106816],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9940247,0.0018040319,0.0016583813,0.0010459775,0.00057803275,0.00088887225],"domain_scores_gemma":[0.99150026,0.006478148,0.00063586934,0.0005565888,0.00022275718,0.0006063775],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005558422,0.0006620184,0.002930566,0.00022810283,0.00017447124,0.00004487546,0.00042550077,0.00033728953,0.00015123317],"category_scores_gemma":[0.000890658,0.0003075242,0.00036252994,0.00073221826,0.00091628614,0.00006524243,0.00017355953,0.0021624956,0.00013274186],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.059279066,0.0045547276,0.10212466,0.0066219787,0.0017371381,0.039606594,0.000010581137,0.000009261797,0.0000046940986,0.000006468028,0.011958775,0.77408606],"study_design_scores_gemma":[0.020063639,0.0075317067,0.012739473,0.0025215123,0.002655686,0.000104739,0.000003406374,0.00012409732,0.0000016601226,1.8648373e-7,0.9538998,0.0003541229],"about_ca_topic_score_codex":0.0000624822,"about_ca_topic_score_gemma":0.00010184422,"teacher_disagreement_score":0.941941,"about_ca_system_score_codex":0.00019276892,"about_ca_system_score_gemma":0.0010219073,"threshold_uncertainty_score":0.9999377},"labels":[],"label_agreement":null},{"id":"W1980626997","doi":"10.1097/wnf.0b013e31804c780e","title":"Gambling and Increased Sexual Desire With Dopaminergic Medications in Restless Legs Syndrome","year":2007,"lang":"en","type":"article","venue":"Clinical Neuropharmacology","topic":"Restless Legs Syndrome Research","field":"Medicine","cited_by":137,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre for Movement Disorders","funders":"","keywords":"Pramipexole; Ropinirole; Restless legs syndrome; Dopaminergic; Psychology; Levodopa; Parkinson's disease; Mania; Psychiatry; Dopamine agonist; Disease; Medicine; Internal medicine; Dopamine; Bipolar disorder; Neuroscience; Neurology; Mood","score_opus":0.11062389079381042,"score_gpt":0.4626233068166211,"score_spread":0.3519994160228107,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1980626997","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9955523,0.00028565564,0.000054566535,0.002127473,0.00018468076,0.0006146126,0.000003190841,0.00007644807,0.0011010991],"genre_scores_gemma":[0.997,0.00034896506,0.00056287675,0.0013401185,0.00018204868,0.00003350298,0.000012657958,0.000050679635,0.00046916085],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9968989,0.0004968231,0.0008676041,0.0006822763,0.00040999718,0.0006443883],"domain_scores_gemma":[0.99510974,0.0035255405,0.00013217672,0.00036643722,0.00013236268,0.0007337274],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0022431177,0.00020818984,0.000652283,0.00042425387,0.00007816214,0.000015459844,0.00021461242,0.00023296768,0.00018221677],"category_scores_gemma":[0.0010601848,0.00016847353,0.000047777674,0.0006482834,0.00090122235,0.000068649664,0.00015514536,0.0012978046,0.00006668826],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0032913934,0.0017178656,0.90396774,0.0003114352,0.00019462245,0.051935934,0.000055062206,0.000012958287,0.02570321,0.00037855937,0.0005134748,0.011917732],"study_design_scores_gemma":[0.0065716077,0.002075123,0.98435396,0.00007013638,0.00012681543,0.004660736,0.00006209308,0.0003932416,0.0002526369,0.000025647108,0.0012386127,0.0001693622],"about_ca_topic_score_codex":0.000084825406,"about_ca_topic_score_gemma":0.000049822127,"teacher_disagreement_score":0.08038624,"about_ca_system_score_codex":0.000058210546,"about_ca_system_score_gemma":0.00033111285,"threshold_uncertainty_score":0.6870151},"labels":[],"label_agreement":null},{"id":"W1980632974","doi":"10.1097/wnf.0b013e31827db49b","title":"Safety and Pharmacology of a Single Intravenous Dose of Ponezumab in Subjects With Mild-to-Moderate Alzheimer Disease","year":2013,"lang":"en","type":"article","venue":"Clinical Neuropharmacology","topic":"Alzheimer's disease research and treatments","field":"Medicine","cited_by":86,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Parkwood Institute","funders":"","keywords":"Medicine; Adverse effect; Pharmacokinetics; Placebo; Anesthesia; Pharmacodynamics; Cerebrospinal fluid; Gastroenterology; Internal medicine; Pathology","score_opus":0.05818489725870915,"score_gpt":0.3828051632185218,"score_spread":0.32462026595981264,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1980632974","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9938141,0.0020553926,0.0000042416978,0.0020029389,0.00017188107,0.0017118378,0.000037694077,0.000022013679,0.00017990533],"genre_scores_gemma":[0.99680644,0.00076650473,0.00021605169,0.001960091,0.00009634395,0.0000870447,0.000014300224,0.000036871515,0.00001636952],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9974439,0.00051887904,0.00079884287,0.0005260207,0.000221569,0.00049076707],"domain_scores_gemma":[0.997402,0.0009046599,0.00017613599,0.000234743,0.00023344302,0.0010490107],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021315982,0.00022744344,0.0008369448,0.00022258551,0.00003662262,0.0000052669084,0.00012787183,0.00009835115,0.00057784276],"category_scores_gemma":[0.00016176645,0.00017600074,0.00010439873,0.00031515546,0.00054801255,0.00007489184,0.0001449778,0.000348327,0.000054775966],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.22950189,0.037229676,0.5123551,0.00074332394,0.018015478,0.010399158,0.00041306557,0.00016849938,0.15173626,0.00013605459,0.00262016,0.036681358],"study_design_scores_gemma":[0.02309526,0.008696906,0.95114124,0.000072611896,0.0022389756,0.00005048123,0.000020048525,0.00061162247,0.013625367,0.00006497737,0.00016598593,0.000216497],"about_ca_topic_score_codex":0.00007502784,"about_ca_topic_score_gemma":0.0000064643696,"teacher_disagreement_score":0.43878618,"about_ca_system_score_codex":0.000026538479,"about_ca_system_score_gemma":0.00042112064,"threshold_uncertainty_score":0.7177102},"labels":[],"label_agreement":null},{"id":"W1980849388","doi":"10.1097/01.wnf.0000174932.82134.e2","title":"Quetiapine for Insomnia in Parkinson Disease","year":2005,"lang":"en","type":"article","venue":"Clinical Neuropharmacology","topic":"Restless Legs Syndrome Research","field":"Medicine","cited_by":79,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre for Movement Disorders","funders":"","keywords":"Quetiapine; Pittsburgh Sleep Quality Index; Epworth Sleepiness Scale; Insomnia; Internal medicine; Medicine; Excessive daytime sleepiness; Rating scale; Polysomnography; Hypnotic; Psychology; Anesthesia; Sleep disorder; Psychiatry; Schizophrenia (object-oriented programming); Sleep quality","score_opus":0.1265459834756793,"score_gpt":0.5002710878749101,"score_spread":0.37372510439923085,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1980849388","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96757877,0.0005042959,0.000036273475,0.029765025,0.00039569673,0.0011968961,0.000009117079,0.0000661781,0.0004477696],"genre_scores_gemma":[0.9877145,0.0012569476,0.000759011,0.0074529,0.0011105813,0.00020379123,0.000014254805,0.000047265363,0.0014406955],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9976132,0.00036545613,0.00074873515,0.00055421906,0.00019898762,0.0005193864],"domain_scores_gemma":[0.9973416,0.0015292998,0.0000777251,0.0003121152,0.000096978125,0.00064233626],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00069207203,0.00015434092,0.0005090309,0.00019239508,0.000036175425,0.000009085902,0.00020646882,0.00013901452,0.0005023231],"category_scores_gemma":[0.0022639828,0.00013890384,0.00020760507,0.00023565475,0.00026054672,0.00006390463,0.00011007006,0.00068549043,0.0003811086],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014511314,0.006276665,0.7650221,0.0005034597,0.00012055362,0.0037593788,0.000034175653,0.00015470285,0.01701704,0.0006306124,0.06479334,0.12717663],"study_design_scores_gemma":[0.006519618,0.00068250403,0.45944357,0.000019389769,0.000048378773,0.000028017406,0.0000011762287,0.003703334,0.00022992528,0.000062228726,0.5291673,0.00009458454],"about_ca_topic_score_codex":0.0000039951474,"about_ca_topic_score_gemma":0.0000056497097,"teacher_disagreement_score":0.46437395,"about_ca_system_score_codex":0.00006674686,"about_ca_system_score_gemma":0.00028095895,"threshold_uncertainty_score":0.5664334},"labels":[],"label_agreement":null},{"id":"W1986554664","doi":"10.1097/00002826-200107000-00010","title":"Amoxapine Shows an Antipsychotic Effect but Worsens Motor Function in Patients with Parkinson's Disease and Psychosis","year":2001,"lang":"en","type":"article","venue":"Clinical Neuropharmacology","topic":"Schizophrenia research and treatment","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto Western Hospital; University of Toronto","funders":"","keywords":"Antipsychotic; Psychosis; Medicine; Parkinson's disease; Concomitant; Disease; Motor function; Antidepressant; Schizophrenia (object-oriented programming); Psychiatry; Antipsychotic drug; Internal medicine; Physical medicine and rehabilitation","score_opus":0.029953791314842437,"score_gpt":0.3633971418893481,"score_spread":0.33344335057450564,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1986554664","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9969232,0.00012090905,0.000005650268,0.0010432774,0.00052642945,0.0012733077,0.00001469181,0.00006116942,0.000031356543],"genre_scores_gemma":[0.9968581,0.00055959256,0.000114043185,0.0018602778,0.00029937772,0.00010197009,0.000037980506,0.000035328,0.00013330019],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99770784,0.000596246,0.0003749235,0.0006695922,0.00023625798,0.00041513747],"domain_scores_gemma":[0.9980886,0.0005473902,0.000073642404,0.00030488594,0.000069617236,0.000915861],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00025678368,0.00022152613,0.00045139098,0.00016671207,0.00006137778,0.000015694219,0.00007638419,0.000091982474,0.00027701087],"category_scores_gemma":[0.00025411166,0.00015619452,0.000086265245,0.0002424141,0.00023500771,0.00008718141,0.000036663016,0.00047841185,0.0000584511],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.1572232,0.0024164524,0.8028752,0.00002459269,0.0000986398,0.0009475657,0.0000024059482,0.0000011189746,0.00014071705,0.0000034650222,0.00024560365,0.036021],"study_design_scores_gemma":[0.030457417,0.01617524,0.9509351,0.000026804826,0.00032333488,0.000013759776,0.0000013197051,0.00038725586,0.000010128694,0.000023069622,0.0015239103,0.00012260993],"about_ca_topic_score_codex":0.000009419278,"about_ca_topic_score_gemma":0.000028370385,"teacher_disagreement_score":0.1480599,"about_ca_system_score_codex":0.000029475339,"about_ca_system_score_gemma":0.000054475302,"threshold_uncertainty_score":0.6369428},"labels":[],"label_agreement":null},{"id":"W1987370838","doi":"10.1097/wnf.0b013e31815cba61","title":"Variability of the In Vivo Metabolism of Clozapine","year":2008,"lang":"en","type":"article","venue":"Clinical Neuropharmacology","topic":"Schizophrenia research and treatment","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"National Defense Medical College","keywords":"Clozapine; Metabolite; In vivo; Schizophrenia (object-oriented programming); Pharmacology; Antipsychotic; Atypical antipsychotic; Metabolism; Psychology; Chemistry; Endocrinology; Internal medicine; Medicine; Biology; Psychiatry","score_opus":0.07665838262348112,"score_gpt":0.4100766655505208,"score_spread":0.3334182829270397,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1987370838","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9966419,0.00016935481,0.0000021672124,0.0019067947,0.00046812356,0.00040981334,0.000011699752,0.000008389334,0.00038180803],"genre_scores_gemma":[0.9978287,0.0009171294,0.00033430898,0.000644516,0.00011493864,0.000013906377,5.9430147e-7,0.000008219364,0.00013769415],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99795586,0.0007754461,0.0006764967,0.00022740953,0.00018440737,0.00018036587],"domain_scores_gemma":[0.99784154,0.0014632329,0.00012696526,0.00033787353,0.00010437634,0.00012601301],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005615302,0.00008405674,0.00051723997,0.000054180273,0.000021085556,3.6953844e-7,0.00016352147,0.00008056752,0.00056296255],"category_scores_gemma":[0.002001948,0.000050837127,0.00022206777,0.0002855138,0.0007051566,0.000014519837,0.00012958949,0.00039232703,0.000008780518],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015620148,0.0041324636,0.92328775,0.00007292864,0.00017042326,0.00042023382,0.000040963274,0.000007640471,0.050908886,0.00088678184,0.0016081275,0.0028436312],"study_design_scores_gemma":[0.008808807,0.0004945427,0.96915287,0.0000073247775,0.00008724402,0.000050732382,0.0000014167148,0.00008497618,0.018983135,0.00025579118,0.0020412053,0.00003193755],"about_ca_topic_score_codex":0.000024939785,"about_ca_topic_score_gemma":0.0000055318365,"teacher_disagreement_score":0.045865115,"about_ca_system_score_codex":0.000013485683,"about_ca_system_score_gemma":0.00031690337,"threshold_uncertainty_score":0.61640453},"labels":[],"label_agreement":null},{"id":"W1993332355","doi":"10.1097/00002826-200401000-00008","title":"Effect of Riluzole on Dyskinesia and Duration of the ON State in Parkinson Disease Patients","year":2004,"lang":"en","type":"article","venue":"Clinical Neuropharmacology","topic":"Parkinson's Disease Mechanisms and Treatments","field":"Medicine","cited_by":49,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre for Movement Disorders","funders":"","keywords":"Riluzole; Dyskinesia; Placebo; Levodopa; Apomorphine; Parkinson's disease; Anesthesia; Medicine; Psychology; Amyotrophic lateral sclerosis; Internal medicine; Disease; Dopaminergic; Dopamine","score_opus":0.016343561423508103,"score_gpt":0.3469000184184506,"score_spread":0.33055645699494246,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1993332355","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9984758,0.00003171367,0.0000015547704,0.00031905007,0.00040306538,0.0006834714,0.000029158171,0.0000084868,0.000047710004],"genre_scores_gemma":[0.9987602,0.00013912536,0.000006199511,0.0010059165,0.00003010739,0.000023055694,0.000006970782,0.000012996393,0.000015382988],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985945,0.0004176819,0.0004300803,0.000266949,0.00015811196,0.00013266003],"domain_scores_gemma":[0.99899316,0.00046100907,0.00018335067,0.00017604842,0.000033407476,0.00015300003],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018539894,0.00012497828,0.00033091777,0.000063179665,0.000022570111,0.0000016057072,0.000060733528,0.00004666003,0.000015308002],"category_scores_gemma":[0.00041723443,0.000077729754,0.000106307656,0.00011302304,0.000121700585,0.00001931984,0.000038797367,0.0001699806,0.000010103896],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013343233,0.0031734947,0.97156054,0.00013055831,0.000050691517,0.0001862868,0.000017843848,0.0001226019,0.0020301773,0.00006015958,0.00004202916,0.009282356],"study_design_scores_gemma":[0.013317401,0.0058090314,0.9679352,0.00007581603,0.0001635911,8.389151e-7,3.6730827e-7,0.00007320749,0.012068039,0.00015566364,0.00035418101,0.000046637313],"about_ca_topic_score_codex":0.000006889175,"about_ca_topic_score_gemma":0.0000014239824,"teacher_disagreement_score":0.010037862,"about_ca_system_score_codex":0.000026571035,"about_ca_system_score_gemma":0.00005089965,"threshold_uncertainty_score":0.31697273},"labels":[],"label_agreement":null},{"id":"W2002651101","doi":"10.1097/wnf.0b013e318263163c","title":"Immunogenicity and Long-Term Efficacy of Botulinum Toxin Type B in the Treatment of Cervical Dystonia","year":2012,"lang":"en","type":"article","venue":"Clinical Neuropharmacology","topic":"Botulinum Toxin and Related Neurological Disorders","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Cervical dystonia; Immunogenicity; Medicine; Botulinum toxin; Seroconversion; Adverse effect; Internal medicine; Clinical trial; Botulism; Spasmodic Torticollis; Antibody; Immunology; Surgery; Torticollis; Biology","score_opus":0.07284874114159376,"score_gpt":0.4068194709946589,"score_spread":0.3339707298530652,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2002651101","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99434096,0.0025050293,0.0000014862543,0.0017967077,0.0006213716,0.0005416152,0.0000032293249,0.000016232236,0.0001734012],"genre_scores_gemma":[0.9886231,0.008897773,0.000029116673,0.0022399074,0.00014205776,0.000007447779,0.000004334722,0.000014076403,0.000042202784],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99785197,0.00067764695,0.00077462615,0.00025577884,0.0001255469,0.0003144165],"domain_scores_gemma":[0.997346,0.0020416528,0.00015852935,0.00025521018,0.00004123074,0.00015736998],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00034234222,0.00016247411,0.00061219046,0.000054763153,0.000026857822,0.000001955898,0.00014566448,0.00027271837,0.00021358556],"category_scores_gemma":[0.00027574136,0.000093894916,0.00020347284,0.00024652056,0.00060263247,0.000023935736,0.000051765845,0.00044722547,0.000023280587],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0054913843,0.012398513,0.9388521,0.00006832629,0.00018931949,0.00022191848,0.00031724037,0.0000040528257,0.030358925,0.0000981082,0.0001162054,0.011883951],"study_design_scores_gemma":[0.007106402,0.006229523,0.9837129,0.00000973687,0.0003189156,0.00008638786,0.000009839233,0.000038322618,0.0014023562,0.00001426347,0.0009987118,0.00007261274],"about_ca_topic_score_codex":0.0000053162867,"about_ca_topic_score_gemma":0.0000017338623,"teacher_disagreement_score":0.044860873,"about_ca_system_score_codex":0.00001083682,"about_ca_system_score_gemma":0.000037002854,"threshold_uncertainty_score":0.38289234},"labels":[],"label_agreement":null},{"id":"W2005346374","doi":"10.1097/00002826-200007000-00003","title":"Mexiletine in the Treatment of Torticollis and Generalized Dystonia","year":2000,"lang":"en","type":"article","venue":"Clinical Neuropharmacology","topic":"Botulinum Toxin and Related Neurological Disorders","field":"Medicine","cited_by":42,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Spasmodic Torticollis; Mexiletine; Dystonia; Medicine; Anesthesia; Torticollis; Rating scale; Trihexyphenidyl; Adverse effect; Psychology; Internal medicine; Surgery; Psychiatry","score_opus":0.052729010682651935,"score_gpt":0.395296412991609,"score_spread":0.34256740230895705,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2005346374","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98695195,0.00057508104,2.962692e-7,0.010449869,0.00017496839,0.0004585388,0.0000025990535,0.000019411249,0.001367304],"genre_scores_gemma":[0.960528,0.02692422,0.00005916498,0.011785617,0.00009821646,0.000024313333,0.000002546685,0.000010030228,0.0005678535],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9983907,0.00051712664,0.0005474116,0.00027154898,0.00008417669,0.00018908657],"domain_scores_gemma":[0.99882793,0.00083845446,0.000056761288,0.00016286838,0.000015744607,0.00009821215],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00016781154,0.00011719152,0.00042507664,0.00003272731,0.000027686274,0.0000028028396,0.00007881401,0.00015177867,0.0013868463],"category_scores_gemma":[0.0000787386,0.00006326278,0.00012854954,0.00016010879,0.00038156714,0.000010356155,0.0000095662845,0.00025127188,0.000036334968],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.024448946,0.032988865,0.3380188,0.00013190026,0.00066208304,0.009070079,0.0011858518,0.00024637225,0.053102467,0.0007272877,0.009645522,0.5297718],"study_design_scores_gemma":[0.016867302,0.012633247,0.7881312,0.00000771067,0.0003937542,0.0001989359,0.000010428488,0.001014546,0.0005482247,0.0001746665,0.17989339,0.00012664474],"about_ca_topic_score_codex":0.000012328998,"about_ca_topic_score_gemma":0.000002517173,"teacher_disagreement_score":0.52964514,"about_ca_system_score_codex":0.0000060013945,"about_ca_system_score_gemma":0.000021114833,"threshold_uncertainty_score":0.999526},"labels":[],"label_agreement":null},{"id":"W2007751663","doi":"10.1097/wnf.0000000000000016","title":"Cannabis (Medical Marijuana) Treatment for Motor and Non–Motor Symptoms of Parkinson Disease","year":2014,"lang":"en","type":"article","venue":"Clinical Neuropharmacology","topic":"Cannabis and Cannabinoid Research","field":"Medicine","cited_by":214,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Cannabis; Medicine; Rating scale; McGill Pain Questionnaire; Parkinson's disease; Disease; Observational study; Physical therapy; Visual analogue scale; Psychiatry; Psychology; Internal medicine","score_opus":0.031976687118068566,"score_gpt":0.3959902137891548,"score_spread":0.3640135266710862,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2007751663","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9683312,0.00024010529,0.00006840613,0.028879752,0.00083717867,0.0013494802,0.00007837303,0.00003429586,0.00018121414],"genre_scores_gemma":[0.9826132,0.00073937624,0.00011210894,0.005564318,0.0010412144,0.00041424288,0.000020665588,0.000050523606,0.009444319],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9975976,0.00029181736,0.00069709704,0.0006046975,0.00034208817,0.00046669762],"domain_scores_gemma":[0.9974686,0.0004390438,0.00013642816,0.00033858677,0.00018754078,0.0014297864],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00064490864,0.0002175108,0.0007471908,0.00011575,0.000074966425,0.000009907232,0.0001687926,0.00020171596,0.00041694095],"category_scores_gemma":[0.0021058128,0.00016709005,0.0003624765,0.0001096525,0.0006905804,0.000026503825,0.00012488101,0.00030971062,0.000013752621],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.026846653,0.0056189173,0.2503859,0.0011723295,0.0006037054,0.00070624606,0.00005676871,0.0000027715778,0.018532032,0.0004962467,0.1763035,0.51927495],"study_design_scores_gemma":[0.008069527,0.009765512,0.46452016,0.000023900631,0.00028866902,0.000017862541,0.0000033760266,0.005931109,0.00026713897,0.000035013712,0.51095873,0.00011903156],"about_ca_topic_score_codex":0.00004436255,"about_ca_topic_score_gemma":0.000009050245,"teacher_disagreement_score":0.5191559,"about_ca_system_score_codex":0.000051582218,"about_ca_system_score_gemma":0.00055157044,"threshold_uncertainty_score":0.6813735},"labels":[],"label_agreement":null},{"id":"W2018391979","doi":"10.1097/00002826-200007000-00005","title":"Sustained Cabergoline Treatment Reverses Levodopa-Induced Dyskinesias in Parkinsonian Monkeys","year":2000,"lang":"en","type":"article","venue":"Clinical Neuropharmacology","topic":"Parkinson's Disease Mechanisms and Treatments","field":"Medicine","cited_by":73,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"","keywords":"Cabergoline; Benserazide; Dyskinesia; Levodopa; Dopamine; Medicine; Parkinson's disease; MPTP; Decarboxylase inhibitor; Dopamine agonist; Agonist; Dopamine receptor D2; Internal medicine; Anesthesia; Pharmacology; Endocrinology; Receptor; Dopaminergic; Disease; Prolactin","score_opus":0.06180993642833334,"score_gpt":0.3893135241711484,"score_spread":0.32750358774281507,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2018391979","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9919433,0.00021607715,0.0000018587758,0.002611743,0.00063335936,0.000953904,0.00002330386,0.00014098872,0.0034754663],"genre_scores_gemma":[0.9867406,0.0030051125,0.00020979678,0.004351181,0.00051081524,0.00012124832,0.000037602833,0.00006360506,0.0049600354],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99678767,0.0005227002,0.00090957177,0.0008887204,0.00020153399,0.0006898012],"domain_scores_gemma":[0.9982344,0.000489657,0.00012785199,0.00044949024,0.000071852,0.00062675745],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0001839815,0.00040570318,0.00095037866,0.00018349895,0.00008946373,0.000013176659,0.00015569627,0.00023830745,0.0041379007],"category_scores_gemma":[0.00019374886,0.00033510933,0.00035029557,0.00037372677,0.00012362131,0.00007225907,0.000059492693,0.00037766498,0.0006910533],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.021069074,0.02646527,0.23673093,0.00013642636,0.0012438927,0.08258735,0.00022311485,0.000083899504,0.019806972,0.00018033489,0.006863059,0.60460967],"study_design_scores_gemma":[0.049551696,0.009479269,0.6937565,0.00007108063,0.0012840875,0.00036109207,0.00005994932,0.0014408277,0.0062068366,0.0002558895,0.23688431,0.00064846344],"about_ca_topic_score_codex":0.00011665385,"about_ca_topic_score_gemma":0.000041613792,"teacher_disagreement_score":0.6039612,"about_ca_system_score_codex":0.00021844874,"about_ca_system_score_gemma":0.00030689928,"threshold_uncertainty_score":0.9999101},"labels":[],"label_agreement":null},{"id":"W2018810282","doi":"10.1097/00002826-200105000-00005","title":"Double-blind, Crossover, Placebo-controlled Trial of Bromocriptine in Patients with Sleep Bruxism","year":2001,"lang":"en","type":"article","venue":"Clinical Neuropharmacology","topic":"Temporomandibular Joint Disorders","field":"Health Professions","cited_by":92,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Hôpital du Sacré-Cœur de Montréal","funders":"","keywords":"Bromocriptine; Placebo; Crossover study; Medicine; Sleep Bruxism; Anesthesia; Internal medicine; Electromyography; Hormone; Prolactin; Physical medicine and rehabilitation","score_opus":0.08322264891113389,"score_gpt":0.46124257906078703,"score_spread":0.3780199301496531,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2018810282","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9816843,0.000035705758,0.000017208924,0.0020115424,0.004841778,0.008259929,0.000011709582,0.000092168004,0.003045609],"genre_scores_gemma":[0.9945862,0.000097842516,0.00013221941,0.0029362522,0.00044577802,0.00057570345,0.00002644744,0.00006915256,0.0011303534],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9928456,0.0026783366,0.0026264652,0.0006749024,0.00036348018,0.0008112022],"domain_scores_gemma":[0.9940886,0.0038709778,0.001042362,0.0004709171,0.00026224865,0.00026493001],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0015669077,0.0003129757,0.0014625025,0.00023636158,0.00020013946,0.0000055538485,0.00040736637,0.00045141566,0.0010392634],"category_scores_gemma":[0.0011639156,0.00024799607,0.00023429861,0.0004306741,0.00036495054,0.00013038535,0.00022408637,0.0018005106,0.00020976098],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7598275,0.0025860542,0.23292379,0.000031364674,0.00009678983,0.00007353192,0.00008464687,0.000022570315,0.000038689537,0.000054030475,0.0039793365,0.0002816847],"study_design_scores_gemma":[0.88181025,0.0036330333,0.1003219,0.000027305925,0.00012283794,0.0000010108449,0.000023617136,0.00008206285,0.0000041334347,0.00005419873,0.013718571,0.0002010667],"about_ca_topic_score_codex":0.000079705875,"about_ca_topic_score_gemma":0.00015908408,"teacher_disagreement_score":0.13260189,"about_ca_system_score_codex":0.000059007965,"about_ca_system_score_gemma":0.0002978085,"threshold_uncertainty_score":0.99999726},"labels":[],"label_agreement":null},{"id":"W2025416757","doi":"10.1097/00002826-200109000-00002","title":"Acute Spinal Cord Injury, Part I: Pathophysiologic Mechanisms","year":2001,"lang":"en","type":"review","venue":"Clinical Neuropharmacology","topic":"Spinal Cord Injury Research","field":"Medicine","cited_by":730,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; University of British Columbia","funders":"","keywords":"Medicine; Spinal cord injury; Excitotoxicity; Neuroprotection; Pathophysiology; Neuroscience; Ischemia; Intensive care medicine; Spinal cord; Pathology; Internal medicine; Psychology; Psychiatry; Glutamate receptor","score_opus":0.32552044224916427,"score_gpt":0.587321250806737,"score_spread":0.26180080855757276,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2025416757","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0012326083,0.98491406,0.000058098718,0.00049563264,0.008023792,0.0035973373,0.00012797723,0.0003254869,0.0012250018],"genre_scores_gemma":[0.000022045562,0.98456323,0.0006689502,0.006276651,0.0033600053,0.00047121616,0.00016337569,0.00021884669,0.0042556613],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9906184,0.0025990738,0.0028348824,0.00199269,0.00061413634,0.0013407938],"domain_scores_gemma":[0.9950735,0.0014102068,0.00088686595,0.0012308084,0.00031868703,0.0010799487],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["research_integrity","insufficient_payload"],"category_scores_codex":[0.0011905802,0.0010171178,0.005772577,0.00044842492,0.00016467771,0.000034082077,0.0011330412,0.0014265941,0.004417369],"category_scores_gemma":[0.0014799963,0.0007684968,0.0023772651,0.0011839847,0.0007866217,0.00006320194,0.0010201827,0.005377883,0.0068380567],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012600913,0.00082737196,0.0000035818266,0.0031908199,0.0006679204,0.009526643,1.571066e-7,5.057681e-9,0.00021953748,0.00009711933,0.02685858,0.9460074],"study_design_scores_gemma":[0.0012149949,0.07497404,0.000029973247,0.0016810546,0.0051749763,0.0014686891,7.9935023e-7,0.0000052392743,0.000011495261,0.00020892386,0.91470665,0.0005231765],"about_ca_topic_score_codex":0.0000020733744,"about_ca_topic_score_gemma":1.5512448e-7,"teacher_disagreement_score":0.94548416,"about_ca_system_score_codex":0.00016581205,"about_ca_system_score_gemma":0.0011463237,"threshold_uncertainty_score":0.99986976},"labels":[],"label_agreement":null},{"id":"W2028210993","doi":"10.1097/wnf.0b013e3181ac155b","title":"Milnacipran","year":2009,"lang":"en","type":"review","venue":"Clinical Neuropharmacology","topic":"Treatment of Major Depression","field":"Medicine","cited_by":44,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"McGill University","keywords":"Milnacipran; Fibromyalgia; Antidepressant; Reuptake inhibitor; Pharmacology; Venlafaxine; Duloxetine; Tolerability; Psychology; Medicine; Internal medicine; Psychiatry; Anxiety; Adverse effect","score_opus":0.29603911199501876,"score_gpt":0.5823993394174389,"score_spread":0.2863602274224202,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2028210993","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00015503906,0.992134,5.9744673e-7,0.00036932685,0.0024284536,0.0015971035,0.000013451373,0.0002505183,0.0030515126],"genre_scores_gemma":[0.000008456893,0.99126744,0.0001992751,0.0036670768,0.0017747622,0.00007115452,0.00009263549,0.0001040285,0.002815188],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99570173,0.0010845312,0.0015624203,0.0009765182,0.00022786313,0.00044695116],"domain_scores_gemma":[0.9962668,0.002004377,0.00047917245,0.0006665722,0.00005733978,0.00052576064],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00031942243,0.00056025694,0.0037963642,0.00020238449,0.00005402402,0.000010047271,0.00031736356,0.0008714118,0.0008400041],"category_scores_gemma":[0.00069623,0.00038753348,0.0016517265,0.00024939206,0.00021489372,0.000029106597,0.00015331751,0.0017987204,0.002806278],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001356816,0.0011543629,0.000034924873,0.0017713242,0.00024510696,0.0031599917,6.653069e-7,1.2611778e-8,0.000001972247,0.000005314846,0.030230653,0.96326],"study_design_scores_gemma":[0.0029359849,0.002069271,0.00041033333,0.0020974497,0.0038812004,0.0006879986,1.2002887e-7,9.3692967e-7,0.0000014214372,0.0000074391396,0.98766583,0.00024201206],"about_ca_topic_score_codex":5.098966e-7,"about_ca_topic_score_gemma":6.378531e-8,"teacher_disagreement_score":0.963018,"about_ca_system_score_codex":0.000055288692,"about_ca_system_score_gemma":0.0003926984,"threshold_uncertainty_score":0.99985766},"labels":[],"label_agreement":null},{"id":"W2028615441","doi":"10.1097/wnf.0000000000000020","title":"Generalized Myoclonus and Spasticity Induced by Lamotrigine Toxicity","year":2014,"lang":"en","type":"review","venue":"Clinical Neuropharmacology","topic":"Epilepsy research and treatment","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"","keywords":"Myoclonus; Lamotrigine; Status epilepticus; Medicine; Anesthesia; Anticonvulsant; Myoclonic Jerk; Epilepsy; Convulsion; Toxicity; Internal medicine; Psychiatry","score_opus":0.15092536508325527,"score_gpt":0.49634606446188906,"score_spread":0.3454206993786338,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2028615441","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.04077878,0.9551432,0.000009927162,0.00068039325,0.000982462,0.0019101527,0.00007482704,0.00011825154,0.00030199767],"genre_scores_gemma":[0.0010516864,0.9935032,0.000134504,0.0028439392,0.0011724847,0.00015580148,0.00014612442,0.00009560038,0.0008966754],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9944336,0.001970331,0.0015040874,0.0011069169,0.00029059392,0.0006945078],"domain_scores_gemma":[0.99427384,0.0035563905,0.000417984,0.0004884534,0.00010952313,0.0011538182],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0007677216,0.0006024789,0.0041333837,0.00016158432,0.000096922886,0.000024128432,0.00025634433,0.0007314058,0.00046149213],"category_scores_gemma":[0.0016914057,0.000428984,0.00073295285,0.00025415912,0.00041881367,0.000026783746,0.00031521206,0.002003423,0.00038553067],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00042716047,0.0014467296,0.00038468605,0.0080344975,0.0010009736,0.001499514,0.0000016959704,2.4407777e-8,0.0001283794,0.00005835065,0.026131116,0.9608869],"study_design_scores_gemma":[0.004719419,0.0031804047,0.00033411098,0.0007111555,0.0029228784,0.0002778775,1.6345936e-7,0.0000270671,0.000018462544,0.000013611866,0.987504,0.00029084666],"about_ca_topic_score_codex":0.000014935465,"about_ca_topic_score_gemma":0.000001971769,"teacher_disagreement_score":0.9613729,"about_ca_system_score_codex":0.00007648972,"about_ca_system_score_gemma":0.00041768097,"threshold_uncertainty_score":0.9998162},"labels":[],"label_agreement":null},{"id":"W2032203345","doi":"10.1097/wnf.0b013e3181f8d4ed","title":"Evidence for Use of Mood Stabilizers and Anticonvulsants in the Treatment of Nonaffective Disorders in Children and Adolescents","year":2010,"lang":"en","type":"review","venue":"Clinical Neuropharmacology","topic":"Child and Adolescent Psychosocial and Emotional Development","field":"Psychology","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University; Hotel Dieu Hospital","funders":"","keywords":"Mood; Mood disorders; Lithium (medication); Psychiatry; Mood stabilizer; Divalproex; Anticonvulsant; Psychology; Bipolar disorder; Lamotrigine; Clinical psychology; Medicine; Mania; Anxiety; Epilepsy","score_opus":0.17072241895368406,"score_gpt":0.4752191105979739,"score_spread":0.30449669164428983,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2032203345","genre_codex":"empirical","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.56542444,0.43072054,0.0000011596443,0.00010606816,0.0009160078,0.0027177779,0.00010127924,0.0000037269567,0.00000901456],"genre_scores_gemma":[0.12750734,0.87213004,0.000019993022,0.00010811241,0.000104220664,0.00008987365,0.000013516216,0.000017866227,0.000009021268],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9970788,0.0010257445,0.0009994298,0.00056446565,0.00008660183,0.0002449596],"domain_scores_gemma":[0.9955202,0.0038273248,0.00038419088,0.00017579361,0.000026269614,0.000066223816],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00041543442,0.0002759892,0.0012897344,0.00013713432,0.000029748495,0.000007095351,0.00019028455,0.0002944107,0.000015263326],"category_scores_gemma":[0.00020773146,0.00018296822,0.00026835737,0.00017696465,0.00047723314,0.00003862189,0.00004363916,0.0004234624,0.000001746641],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00035228286,0.0028610826,0.24429399,0.0010575907,0.000104436775,0.000002623731,0.0002210268,9.376168e-8,0.0000022842955,0.000042373413,0.000043882803,0.75101835],"study_design_scores_gemma":[0.003151534,0.0010928451,0.9607632,0.0024273505,0.00032584165,0.000010861052,0.000012862046,0.0000017635841,3.2444225e-7,0.000055113454,0.031994294,0.00016401008],"about_ca_topic_score_codex":0.00004222296,"about_ca_topic_score_gemma":0.00008484958,"teacher_disagreement_score":0.7508543,"about_ca_system_score_codex":0.000016603155,"about_ca_system_score_gemma":0.000073804986,"threshold_uncertainty_score":0.7461227},"labels":[],"label_agreement":null},{"id":"W2032852860","doi":"10.1097/00002826-200207000-00005","title":"Cognitive Deficits and Striatal Dopaminergic Denervation in Parkinson's Disease: A Single Photon Emission Computed Tomography Study Using 123Iodine-β-CIT in Patients ON and OFF Levodopa","year":2002,"lang":"en","type":"article","venue":"Clinical Neuropharmacology","topic":"Parkinson's Disease Mechanisms and Treatments","field":"Medicine","cited_by":38,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université du Québec à Montréal; Centre Hospitalier de l’Université de Montréal; Ottawa Hospital","funders":"","keywords":"Dopaminergic; Parkinson's disease; Levodopa; Cognition; Denervation; Psychology; Neuroscience; Executive functions; Single-photon emission computed tomography; Audiology; Medicine; Internal medicine; Disease; Dopamine","score_opus":0.0769197879628581,"score_gpt":0.34601148228322126,"score_spread":0.2690916943203632,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2032852860","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9977391,0.0004535137,0.0000024524097,0.00007693927,0.00027526132,0.0013473118,0.00004533654,0.0000334007,0.00002671266],"genre_scores_gemma":[0.9987406,0.0002341983,0.000040337287,0.0008062267,0.000060441733,0.000036217432,0.000039096725,0.000029425915,0.0000134192915],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99755585,0.0005335834,0.0006058416,0.0007616219,0.00022828166,0.0003148468],"domain_scores_gemma":[0.998669,0.0005510144,0.00017557455,0.00012855322,0.0000735272,0.00040229585],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00018650615,0.00027168688,0.00054207025,0.00036315812,0.000072681716,0.000019342637,0.000056197066,0.00010448041,0.000039950348],"category_scores_gemma":[0.0003251452,0.00024648325,0.00007455911,0.0004195476,0.00010893811,0.00008575923,0.000101785,0.00032969212,0.0000046417676],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0038518205,0.011380285,0.9684226,0.000032877044,0.0000617782,0.0010565659,0.000054122716,0.000008209735,0.0005897688,0.0000015073342,0.000025578609,0.014514924],"study_design_scores_gemma":[0.026317472,0.0040854514,0.9594182,0.00014256281,0.00031461046,0.000005111846,0.000030904153,0.009150835,0.00014237591,0.00001221584,0.00020155248,0.00017872007],"about_ca_topic_score_codex":0.000019240631,"about_ca_topic_score_gemma":0.0000068498834,"teacher_disagreement_score":0.02246565,"about_ca_system_score_codex":0.00005308188,"about_ca_system_score_gemma":0.000024943072,"threshold_uncertainty_score":0.99999875},"labels":[],"label_agreement":null},{"id":"W2033461129","doi":"10.1097/00002826-200309000-00006","title":"Lamotrigine Treatment for Post-Stroke Pathological Laughing and Crying","year":2003,"lang":"en","type":"article","venue":"Clinical Neuropharmacology","topic":"Infant Health and Development","field":"Health Professions","cited_by":45,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Foothills Medical Centre","funders":"","keywords":"Lamotrigine; Crying; Stroke (engine); Medicine; Mood; Pathological; Anesthesia; Serotonin reuptake inhibitor; Epilepsy; Psychology; Pediatrics; Antidepressant; Psychiatry; Internal medicine","score_opus":0.21654628396358494,"score_gpt":0.5531428008630249,"score_spread":0.33659651689944,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2033461129","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98804045,0.00030084763,0.0002627775,0.003082986,0.0035861589,0.0016655806,0.000049747425,0.000116662144,0.0028947743],"genre_scores_gemma":[0.9212451,0.001971782,0.00831329,0.061783344,0.0009124263,0.0006622538,0.00001983916,0.00004838964,0.005043606],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9959306,0.0016293788,0.0010593387,0.000516307,0.000070375405,0.0007940084],"domain_scores_gemma":[0.9917941,0.007251649,0.00022483284,0.00015741838,0.00015081112,0.00042119756],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014990168,0.00019939637,0.00052768574,0.00006986232,0.00074046367,0.0000055767896,0.000092283575,0.0003157441,0.00040686072],"category_scores_gemma":[0.0024963694,0.00014961688,0.0001173895,0.000065543485,0.00013410483,0.000043102427,0.00006600929,0.0006434177,0.00016719509],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008019117,0.0028522727,0.7451614,0.0012826796,0.00033111163,0.0014968129,0.0027216522,0.00001126606,0.036870442,0.043720786,0.021927467,0.13560499],"study_design_scores_gemma":[0.012373431,0.0030847378,0.06647924,0.000028159564,0.00010179402,0.000038401336,0.000184107,0.00018790654,0.00026007838,0.00058555126,0.91636616,0.00031041898],"about_ca_topic_score_codex":0.0000077573495,"about_ca_topic_score_gemma":0.0000068742024,"teacher_disagreement_score":0.8944387,"about_ca_system_score_codex":0.00006996786,"about_ca_system_score_gemma":0.0004539,"threshold_uncertainty_score":0.61011994},"labels":[],"label_agreement":null},{"id":"W2039313127","doi":"10.1097/00002826-200203000-00010","title":"Treatment of Excessive Daytime Sleepiness in Patients With Parkinson's Disease With Modafinil","year":2002,"lang":"en","type":"article","venue":"Clinical Neuropharmacology","topic":"Parkinson's Disease Mechanisms and Treatments","field":"Medicine","cited_by":131,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto Western Hospital","funders":"","keywords":"Epworth Sleepiness Scale; Modafinil; Parkinson's disease; Dopamine agonist; Dopaminergic; Excessive daytime sleepiness; Medicine; Levodopa; Psychology; Internal medicine; Anesthesia; Dopamine; Disease; Psychiatry; Sleep disorder; Polysomnography; Insomnia","score_opus":0.03507027948667208,"score_gpt":0.318900012094994,"score_spread":0.28382973260832195,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2039313127","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9976143,0.00026100475,0.000010531973,0.000506731,0.00021800613,0.00096386863,0.00007406788,0.000041389027,0.00031009992],"genre_scores_gemma":[0.9980791,0.00042027744,0.0002106448,0.00069312315,0.000094192415,0.0001370101,0.000043082942,0.00004743172,0.00027511647],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979421,0.00022879975,0.00053015014,0.00065683515,0.00026625642,0.00037585472],"domain_scores_gemma":[0.9983924,0.00028376086,0.00024449124,0.0003693766,0.00013330484,0.0005766553],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000044249464,0.0003074958,0.00077872095,0.00013545834,0.00004157741,0.000005400588,0.000106688974,0.00008639347,0.0005739303],"category_scores_gemma":[0.000065827706,0.00019797074,0.00013898127,0.0002767294,0.00025342367,0.000069863134,0.000034013272,0.00015527154,0.00006957109],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010634311,0.015445382,0.95521104,0.000043277843,0.00031077117,0.0034040466,0.000029937439,0.000036485937,0.00002694699,0.000016167285,0.00010204754,0.014739568],"study_design_scores_gemma":[0.03554815,0.009949894,0.9443403,0.000042171418,0.00077397807,0.000007418675,0.0000033718277,0.0008926468,0.00009445132,0.000012703799,0.008158862,0.00017605074],"about_ca_topic_score_codex":0.000008432555,"about_ca_topic_score_gemma":0.0000022612487,"teacher_disagreement_score":0.02491384,"about_ca_system_score_codex":0.00007023027,"about_ca_system_score_gemma":0.000089163295,"threshold_uncertainty_score":0.8073013},"labels":[],"label_agreement":null},{"id":"W2039473736","doi":"10.1097/00002826-200403000-00009","title":"Antidepressants in the Treatment of Psychosis With Comorbid Depression in Parkinson Disease","year":2004,"lang":"en","type":"article","venue":"Clinical Neuropharmacology","topic":"Parkinson's Disease Mechanisms and Treatments","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network","funders":"","keywords":"Psychosis; Psychiatry; Comorbidity; Depression (economics); Exacerbation; Parkinson's disease; Psychotic depression; Antidepressant; Disease; Depressive symptoms; Medicine; Psychology; Anxiety; Internal medicine","score_opus":0.056266048015690004,"score_gpt":0.39558118217732324,"score_spread":0.3393151341616332,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2039473736","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99693537,0.00077632815,0.0000093208155,0.0010037884,0.00022565256,0.0008586716,0.000018754,0.000017812565,0.00015428406],"genre_scores_gemma":[0.99417585,0.0038578047,0.00013948383,0.001559336,0.000071458504,0.00015048689,0.000012073952,0.000020310586,0.000013194267],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982633,0.0003269948,0.00049064186,0.00046055208,0.00018899763,0.00026954227],"domain_scores_gemma":[0.9989476,0.00034096913,0.00012578357,0.00033897604,0.000025834288,0.00022079416],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001457643,0.0001875128,0.000477958,0.00011316761,0.000030209403,0.0000045243974,0.00013083154,0.000071796865,0.00005283419],"category_scores_gemma":[0.000052997904,0.0001070438,0.00013707651,0.00025168888,0.00015064143,0.000036154415,0.00001861325,0.00017704853,0.000016983287],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0056675365,0.0131482305,0.9673825,0.000024296258,0.00006319102,0.005097032,0.000073791256,0.0000795726,0.0005107441,0.000016585172,0.000046660214,0.007889894],"study_design_scores_gemma":[0.02064956,0.0026552775,0.96744883,0.00007849555,0.00027165707,0.00002298093,0.000013889392,0.0000678332,0.0009507654,0.00011261397,0.007643145,0.00008493025],"about_ca_topic_score_codex":0.000068467336,"about_ca_topic_score_gemma":0.000035005363,"teacher_disagreement_score":0.014982023,"about_ca_system_score_codex":0.000049578637,"about_ca_system_score_gemma":0.00009293285,"threshold_uncertainty_score":0.43651196},"labels":[],"label_agreement":null},{"id":"W2045089703","doi":"10.1097/00002826-200307000-00013","title":"Metabolite Changes Resulting From Treatment in Children With ADHD: A 1H-MRS Study","year":2003,"lang":"en","type":"article","venue":"Clinical Neuropharmacology","topic":"Attention Deficit Hyperactivity Disorder","field":"Medicine","cited_by":82,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"National Research Council Institute for Biodiagnostics; Dalhousie University; Izaak Walton Killam Health Centre; Nova Scotia Health Authority","funders":"Eli Lilly Canada; Nova Scotia Health Research Foundation","keywords":"Phosphocreatine; Creatine; Glutamine; Metabolite; Striatum; Choline; Glutamate receptor; Neurochemical; Internal medicine; Glutamatergic; Attention deficit hyperactivity disorder; Medicine; Endocrinology; Ventral striatum; Psychology; Chemistry; Biochemistry; Dopamine; Psychiatry; Amino acid","score_opus":0.12134737887379468,"score_gpt":0.4435567764725035,"score_spread":0.3222093975987088,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2045089703","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9958424,0.0002563557,0.0000044320545,0.0014606939,0.0004502316,0.0016212509,0.000017989918,0.0000782039,0.00026842163],"genre_scores_gemma":[0.9964447,0.00023750734,0.00021412264,0.0021383278,0.00036129568,0.0001345665,0.00002037093,0.00004813783,0.00040095803],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99680406,0.0013174058,0.0005650695,0.0007512007,0.00018955945,0.0003726851],"domain_scores_gemma":[0.998202,0.0009904105,0.00018437069,0.00035454173,0.00006637596,0.00020224575],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004015811,0.0002553633,0.00078217423,0.00013991885,0.000057860558,0.000011736686,0.00009240694,0.00011886725,0.00032094648],"category_scores_gemma":[0.0007638816,0.00019286573,0.00011048468,0.00031630255,0.00013423953,0.00005273603,0.000043603526,0.000562282,0.00011766515],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008397627,0.006010263,0.9856837,0.0000025470854,0.0004541368,0.00044845167,0.00028592013,0.000016553018,0.0017836993,0.0000056570684,0.000054555545,0.004414772],"study_design_scores_gemma":[0.020356424,0.0036029469,0.96973014,0.000007916142,0.0007856141,0.00006567873,0.00077660126,0.000041212686,0.00018468182,0.0000062545837,0.004268504,0.00017401083],"about_ca_topic_score_codex":0.00020249934,"about_ca_topic_score_gemma":0.00013609779,"teacher_disagreement_score":0.019516662,"about_ca_system_score_codex":0.000044631004,"about_ca_system_score_gemma":0.00011515161,"threshold_uncertainty_score":0.7864836},"labels":[],"label_agreement":null},{"id":"W2045278212","doi":"10.1097/00002826-200403000-00004","title":"Dopaminergic Properties and Experimental Anti-Parkinsonian Effects of IPX750 in Rodent Models of Parkinson Disease","year":2004,"lang":"en","type":"article","venue":"Clinical Neuropharmacology","topic":"Nuclear Receptors and Signaling","field":"Neuroscience","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"National Institute of Neurological Disorders and Stroke; National Institutes of Health","keywords":"Dopaminergic; Dopamine transporter; Dopamine; Pharmacology; Chemistry; Dopamine Plasma Membrane Transport Proteins; Agonist; Biochemistry; Biology; Receptor; Neuroscience","score_opus":0.0680360821334167,"score_gpt":0.3304043789368377,"score_spread":0.262368296803421,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2045278212","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99802136,0.0007204006,0.000010210817,0.00016386044,0.0006374009,0.0003660822,0.0000026809766,0.000022390577,0.000055638444],"genre_scores_gemma":[0.99832386,0.0008601646,0.000042326825,0.00066237466,0.000057044406,0.000015475198,2.2551343e-7,0.000024666906,0.00001384124],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9980381,0.00044076383,0.0006321267,0.00047869937,0.00016551111,0.00024481345],"domain_scores_gemma":[0.9990422,0.00042757197,0.00017848752,0.0001495282,0.000018883225,0.00018329051],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016871611,0.00015344495,0.0004367216,0.00009931341,0.000039279454,0.000008628261,0.00021453816,0.000066099645,0.00001888017],"category_scores_gemma":[0.00035547183,0.00013009775,0.00010109387,0.00015715598,0.00055279856,0.000112683665,0.00017611875,0.00023830598,0.0000046123096],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005223589,0.001092995,0.0047230558,0.00010800286,0.0000045175584,0.00022230428,0.00016150545,0.0038668276,0.9884211,0.0003807998,0.000009621859,0.00048690263],"study_design_scores_gemma":[0.0036576288,0.00082135183,0.0194049,0.000096275144,0.00002649945,0.00000775609,0.000015202775,0.003509522,0.971775,0.0003109791,0.00021747261,0.00015743868],"about_ca_topic_score_codex":0.000020615134,"about_ca_topic_score_gemma":8.129046e-7,"teacher_disagreement_score":0.016646134,"about_ca_system_score_codex":0.000016504193,"about_ca_system_score_gemma":0.000051884086,"threshold_uncertainty_score":0.5305232},"labels":[],"label_agreement":null},{"id":"W2047508973","doi":"10.1097/00002826-200601000-00009","title":"Augmentation Strategies of Clozapine With Antipsychotics in the Treatment of Ultraresistant Schizophrenia","year":2006,"lang":"en","type":"review","venue":"Clinical Neuropharmacology","topic":"Schizophrenia research and treatment","field":"Medicine","cited_by":114,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Research Unit on Children's Psychosocial Maladjustment","funders":"","keywords":"Clozapine; Schizophrenia (object-oriented programming); Antipsychotic; Medicine; Clinical trial; Refractory (planetary science); Psychiatry; Antipsychotic Agent; Psychology; Internal medicine","score_opus":0.14178545408663923,"score_gpt":0.49103547386675445,"score_spread":0.3492500197801152,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2047508973","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.084078915,0.9127204,0.0000047258513,0.0001455496,0.00023844246,0.0025113197,0.00011141212,0.0000164276,0.00017280527],"genre_scores_gemma":[0.011308748,0.98738694,0.0006056744,0.00003701076,0.00023061706,0.00015178998,0.0001933461,0.000041669755,0.00004423046],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9961378,0.001070748,0.0016355817,0.0004861012,0.00035761384,0.0003121829],"domain_scores_gemma":[0.99630004,0.002333648,0.00065978034,0.00048098568,0.00011056131,0.000114979965],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00030386666,0.00039957708,0.0023866065,0.00027094004,0.000029290817,0.00001084743,0.00024202552,0.00022421526,0.0000624509],"category_scores_gemma":[0.00005944722,0.00020039032,0.00057600456,0.0005639374,0.0005553429,0.000031595748,0.00001527281,0.00045761172,0.000012057604],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03724557,0.012543728,0.00089003064,0.007337325,0.0013075017,0.0026175233,0.000043151365,0.000005920896,0.000028217772,0.0007869587,0.0004273347,0.93676674],"study_design_scores_gemma":[0.08047129,0.07587953,0.06072559,0.0062727053,0.016085712,0.00070300186,0.00018547427,0.000027650585,0.00012317192,0.00028335565,0.75855637,0.00068614277],"about_ca_topic_score_codex":0.000028189623,"about_ca_topic_score_gemma":0.00006289006,"teacher_disagreement_score":0.9360806,"about_ca_system_score_codex":0.00007517386,"about_ca_system_score_gemma":0.0010827682,"threshold_uncertainty_score":0.817168},"labels":[],"label_agreement":null},{"id":"W2049816046","doi":"10.1097/00002826-200201000-00005","title":"A Double-Blind Crossover, Placebo-Controlled Study of the Adenosine A2A Antagonist Theophylline in Parkinson's Disease","year":2002,"lang":"en","type":"article","venue":"Clinical Neuropharmacology","topic":"Adenosine and Purinergic Signaling","field":"Biochemistry, Genetics and Molecular Biology","cited_by":45,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre for Movement Disorders","funders":"","keywords":"Theophylline; Crossover study; Antagonist; Placebo; Medicine; Adenosine; Double blind; Anesthesia; Pharmacology; Internal medicine; Pathology","score_opus":0.05653257955031033,"score_gpt":0.35728820973786446,"score_spread":0.30075563018755413,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2049816046","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99483347,0.0018194701,0.000006570435,0.000813963,0.00090174645,0.0013386405,0.000013497941,0.000011807805,0.00026082393],"genre_scores_gemma":[0.99572766,0.0005893266,0.000009585907,0.001644766,0.0007303516,0.00010861677,0.000007230059,0.000033352746,0.0011491085],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9971356,0.00076484896,0.0009628367,0.00061028637,0.00018547598,0.00034094442],"domain_scores_gemma":[0.99854296,0.00034646958,0.00033546728,0.0005182953,0.00008683596,0.00016995256],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00043837467,0.00024706978,0.0005458399,0.000056883997,0.00010821749,0.000017940953,0.00056627125,0.00015846625,0.00024315563],"category_scores_gemma":[0.0003968016,0.00017681137,0.0002836684,0.0002442059,0.00030427324,0.000005192579,0.0003393918,0.00042353728,0.00001447878],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.43000594,0.02224407,0.41541123,0.0000883508,0.00079808343,0.00089327403,0.0002827589,0.0043712095,0.08321408,0.000103472776,0.04162463,0.0009628993],"study_design_scores_gemma":[0.7407561,0.0068928488,0.13440786,0.0000436288,0.001005494,0.000046845795,0.00016274075,0.004426963,0.011199809,0.00008600828,0.09987011,0.0011015693],"about_ca_topic_score_codex":0.000015111281,"about_ca_topic_score_gemma":0.000011352759,"teacher_disagreement_score":0.3107502,"about_ca_system_score_codex":0.000007467981,"about_ca_system_score_gemma":0.000059346832,"threshold_uncertainty_score":0.7210158},"labels":[],"label_agreement":null},{"id":"W2051115769","doi":"10.1097/00002826-200107000-00004","title":"Comparison of Two Dosages of Tolcapone Added to Levodopa in Nonfluctuating Patients with PD","year":2001,"lang":"en","type":"article","venue":"Clinical Neuropharmacology","topic":"Parkinson's Disease Mechanisms and Treatments","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital de l'Enfant-Jésus; Roche (Canada); University of Calgary; Saint John Regional Hospital; Dalhousie University","funders":"","keywords":"Dose; Adverse effect; Levodopa; Nausea; Crossover study; Medicine; Dyskinesia; Tolerability; Anesthesia; Placebo; Internal medicine; Parkinson's disease; Disease","score_opus":0.07501022924080697,"score_gpt":0.4547305578632965,"score_spread":0.37972032862248956,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2051115769","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.998416,0.000054908644,0.00004949324,0.00021461325,0.00026634717,0.00061085494,0.000018431108,0.000018328135,0.00035100846],"genre_scores_gemma":[0.99772644,0.00003265055,0.0011624704,0.0009049629,0.00006158286,0.000022355332,0.000014997956,0.000022636636,0.000051895197],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99807096,0.00023177882,0.00085143646,0.00036614217,0.00021849644,0.00026118755],"domain_scores_gemma":[0.99855834,0.00055669737,0.00027373852,0.00021256658,0.00014664706,0.0002519793],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018080453,0.00015908419,0.0008152039,0.0001437041,0.000020969861,0.0000019914821,0.00011449255,0.00006323701,0.00030621444],"category_scores_gemma":[0.00034973404,0.00012605448,0.00009640941,0.00031450664,0.000108981,0.00003871001,0.00008001233,0.00023149156,0.000027816008],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0043409853,0.004614595,0.9682436,0.000037341037,0.00010156749,0.00024651948,0.00006282496,0.000053509088,0.010903562,0.000019365381,0.00013603034,0.0112401135],"study_design_scores_gemma":[0.015331681,0.00454759,0.9720168,0.000066901106,0.0002516853,0.0000045693896,0.000018227991,0.0003185929,0.00644485,0.000019348034,0.0008805859,0.000099165874],"about_ca_topic_score_codex":0.000024711377,"about_ca_topic_score_gemma":0.00001211751,"teacher_disagreement_score":0.011140947,"about_ca_system_score_codex":0.000021161353,"about_ca_system_score_gemma":0.00006916288,"threshold_uncertainty_score":0.5140352},"labels":[],"label_agreement":null},{"id":"W2052643285","doi":"10.1097/00002826-200107000-00003","title":"Methylphenidate Increases the Motor Effects of L-Dopa in Parkinson's Disease: A Pilot Study","year":2001,"lang":"en","type":"article","venue":"Clinical Neuropharmacology","topic":"Parkinson's Disease Mechanisms and Treatments","field":"Medicine","cited_by":54,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"National Center for Research Resources; National Institute of Neurological Disorders and Stroke","keywords":"Methylphenidate; Anxiety; Levodopa; Anesthesia; Psychology; Dyskinesia; Mood; Dopamine; Placebo; Carbidopa; Stroop effect; Medicine; Parkinson's disease; Cognition; Psychiatry; Internal medicine; Attention deficit hyperactivity disorder; Neuroscience; Disease","score_opus":0.05245199753721957,"score_gpt":0.38186141014338154,"score_spread":0.32940941260616197,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2052643285","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99535155,0.001044498,0.000006322706,0.000631215,0.0006642409,0.002135325,0.000019055651,0.000056375982,0.000091427115],"genre_scores_gemma":[0.99505895,0.0013474661,0.0000411954,0.0027668872,0.00023181007,0.00031290107,0.0000068308523,0.000038328366,0.00019560283],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.996547,0.0014498512,0.00072862563,0.00060950516,0.00027616278,0.00038886626],"domain_scores_gemma":[0.99599963,0.00272974,0.00020892576,0.00048787068,0.00008292632,0.00049090077],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005230202,0.00026149987,0.0007301484,0.00013066117,0.00006837465,0.000008187234,0.0002669476,0.000038305596,0.00019390682],"category_scores_gemma":[0.0016266162,0.0001739149,0.00020044428,0.0003595247,0.00023102466,0.00004844533,0.00018055204,0.00039700675,0.000073405856],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015321091,0.03263186,0.9188526,0.00010495901,0.00043790866,0.018261159,0.0000251117,0.0000039155125,0.0068962555,0.00002545061,0.0003968975,0.007042784],"study_design_scores_gemma":[0.013681135,0.00994823,0.9639504,0.000034694174,0.0011069877,0.000030088053,0.00001651568,0.00015743729,0.00027643025,0.00011228228,0.010562113,0.00012371027],"about_ca_topic_score_codex":0.00013774626,"about_ca_topic_score_gemma":0.00002031294,"teacher_disagreement_score":0.04509777,"about_ca_system_score_codex":0.000031152926,"about_ca_system_score_gemma":0.00015226571,"threshold_uncertainty_score":0.7092044},"labels":[],"label_agreement":null},{"id":"W2054808759","doi":"10.1097/00002826-200305000-00005","title":"Medications and Substances as a Cause of Headache: A Systematic Review of the Literature","year":2003,"lang":"en","type":"review","venue":"Clinical Neuropharmacology","topic":"Migraine and Headache Studies","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Etiology; Medicine; Intensive care medicine; Headaches; Identification (biology); Psychiatry; Biology","score_opus":0.11124576283670541,"score_gpt":0.501474342080962,"score_spread":0.3902285792442566,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2054808759","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00008113375,0.9950926,1.9641838e-7,0.001216117,0.00017650925,0.0028851489,0.000039110077,0.000010081611,0.0004991585],"genre_scores_gemma":[0.000026165657,0.9926688,0.000023115414,0.0050625685,0.00011716487,0.0001837771,0.000011202449,0.000026333144,0.0018808406],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.99475807,0.0020036448,0.0024392395,0.00037372057,0.00024619506,0.00017911034],"domain_scores_gemma":[0.9943619,0.003250164,0.001382603,0.0005931502,0.0002709491,0.00014125012],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001127273,0.00029581375,0.0049359687,0.000079307145,0.000047486254,0.0000025670363,0.00025498663,0.0002775353,0.00009381132],"category_scores_gemma":[0.005134082,0.00015123056,0.0009622552,0.00061478326,0.00065995683,0.0000148707095,0.00011598597,0.0009833573,0.000009635306],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000008269054,0.00016907472,0.000027401215,0.9817955,0.0008583415,0.000044009375,0.000047175254,6.568833e-10,8.0812316e-7,0.00017507987,0.01567261,0.0012017492],"study_design_scores_gemma":[0.00031983238,0.00024358537,0.000023879593,0.5839449,0.01935637,0.00040552922,0.00000767108,1.425701e-7,5.264141e-7,0.000011826977,0.39560366,0.000082075676],"about_ca_topic_score_codex":0.0000012863998,"about_ca_topic_score_gemma":0.0000016764872,"teacher_disagreement_score":0.39785057,"about_ca_system_score_codex":0.0000130685385,"about_ca_system_score_gemma":0.000516703,"threshold_uncertainty_score":0.61670035},"labels":[],"label_agreement":null},{"id":"W2057903762","doi":"10.1097/00002826-200003000-00007","title":"Clinical, Pharmacokinetic, and Pharmacodynamic Effects of Tolcapone Withdrawal in Levodopa-Treated Patients with Parkinsonism","year":2000,"lang":"en","type":"article","venue":"Clinical Neuropharmacology","topic":"Parkinson's Disease Mechanisms and Treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"AXYS Technologies (Canada)","funders":"","keywords":"Levodopa; Discontinuation; Placebo; Pharmacodynamics; Parkinsonism; Pharmacokinetics; Adverse effect; Catechol-O-methyl transferase; Anesthesia; Medicine; Pharmacology; Internal medicine; Psychology; Parkinson's disease; Chemistry","score_opus":0.012767362848147277,"score_gpt":0.3311193104999585,"score_spread":0.31835194765181124,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2057903762","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9964268,0.0005132502,0.0000049477094,0.0001923337,0.0005327396,0.0015275308,0.000034330486,0.00007977367,0.0006883016],"genre_scores_gemma":[0.9918934,0.004607629,0.00030644817,0.0024510638,0.00015661278,0.00007403952,0.00004098976,0.00007106379,0.0003987687],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9960676,0.00086433825,0.0012700899,0.00095041265,0.00030057805,0.0005470265],"domain_scores_gemma":[0.9973106,0.001313622,0.00028910732,0.00031801814,0.00012330653,0.00064535823],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00034069738,0.00041886952,0.0012457711,0.00017720996,0.000063256695,0.000009102663,0.00017168304,0.0002122811,0.0007838383],"category_scores_gemma":[0.00015687966,0.00033098832,0.00020943306,0.0003553642,0.00058517413,0.00009743692,0.000077430006,0.00069207983,0.00007496216],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009279872,0.0076630902,0.7495392,0.00017701536,0.00047146247,0.002108474,0.000018183862,0.000007883068,0.0021890902,0.000005941461,0.00016594805,0.22837387],"study_design_scores_gemma":[0.049548116,0.005146635,0.9252055,0.000110329674,0.0012211326,0.00003155895,0.0000018104979,0.0008532365,0.0013159349,0.000016455486,0.016279496,0.0002697489],"about_ca_topic_score_codex":0.00002663157,"about_ca_topic_score_gemma":0.0000037771915,"teacher_disagreement_score":0.22810411,"about_ca_system_score_codex":0.000035201763,"about_ca_system_score_gemma":0.00011734331,"threshold_uncertainty_score":0.9999142},"labels":[],"label_agreement":null},{"id":"W2068802937","doi":"10.1097/00002826-200601000-00010","title":"Somatic Augmentation Strategies in Clozapine Resistance-What Facts?","year":2006,"lang":"en","type":"review","venue":"Clinical Neuropharmacology","topic":"Electroconvulsive Therapy Studies","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Clozapine; Polypharmacy; Tolerability; Medicine; Electroconvulsive therapy; Rotigotine; Clinical trial; Transcranial magnetic stimulation; Psychiatry; Psychology; Pharmacology; Adverse effect; Internal medicine; Stimulation; Disease; Schizophrenia (object-oriented programming)","score_opus":0.14261878684771034,"score_gpt":0.5178340429518419,"score_spread":0.37521525610413153,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2068802937","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0027581872,0.9919622,0.000007152348,0.0006277288,0.0015023368,0.0024069704,0.000007695676,0.0001088812,0.0006188545],"genre_scores_gemma":[0.0000859264,0.99516505,0.00012786724,0.0015098241,0.0008219873,0.0003442253,0.00012243164,0.00010666871,0.0017160113],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.994522,0.001461495,0.002358982,0.00085231947,0.00023563804,0.00056959176],"domain_scores_gemma":[0.9957599,0.0028359662,0.0007706753,0.00038014754,0.000108214874,0.00014510524],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00042924224,0.0005891068,0.003631198,0.0003354499,0.00006504726,0.000049896116,0.0002670349,0.00045937253,0.00021098305],"category_scores_gemma":[0.00031029663,0.00048039015,0.0006535726,0.0005009566,0.00040769688,0.00019897863,0.000099981975,0.0015963886,0.00024494584],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010991432,0.0012110778,0.00011375811,0.02421229,0.00085493526,0.002177179,0.00004595852,0.0000012747797,0.00015013649,0.00012538841,0.008997569,0.9610113],"study_design_scores_gemma":[0.0051843114,0.0008790002,0.0006455272,0.0045866896,0.0019205852,0.000059973867,0.00003725897,0.00000230035,0.000008963683,0.00022265245,0.98609066,0.00036208608],"about_ca_topic_score_codex":0.000004899961,"about_ca_topic_score_gemma":0.0000431679,"teacher_disagreement_score":0.9770931,"about_ca_system_score_codex":0.00020648002,"about_ca_system_score_gemma":0.0005992816,"threshold_uncertainty_score":0.9997648},"labels":[],"label_agreement":null},{"id":"W2084409189","doi":"10.1097/00002826-200005000-00003","title":"The Relationship between COMT Genotype and the Clinical Effectiveness of Tolcapone, a COMT Inhibitor, in Patients with Parkinson's Disease","year":2000,"lang":"en","type":"article","venue":"Clinical Neuropharmacology","topic":"Parkinson's Disease Mechanisms and Treatments","field":"Medicine","cited_by":40,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Catechol-O-methyl transferase; Genotype; Levodopa; Internal medicine; Parkinson's disease; Clinical trial; Gastroenterology; Medicine; Psychology; Disease; Biology; Genetics; Gene","score_opus":0.041466851835363444,"score_gpt":0.3644804545033011,"score_spread":0.32301360266793766,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2084409189","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99693257,0.00038196554,0.0000040479217,0.00077697396,0.00030144147,0.0014331958,0.000035744564,0.00002244823,0.00011162371],"genre_scores_gemma":[0.9984923,0.0003925038,0.000030072684,0.0007477194,0.00014908242,0.00007715882,0.000026982316,0.000027471639,0.000056697256],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9949062,0.0032670714,0.000833741,0.0004705005,0.00024006504,0.00028242686],"domain_scores_gemma":[0.9813944,0.017581852,0.00020189356,0.00037088143,0.000088269546,0.00036266373],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016054356,0.00020165768,0.00069901184,0.00004421838,0.00017517507,0.000012494092,0.0001641576,0.00012628955,0.00004613877],"category_scores_gemma":[0.0013611789,0.00010623773,0.00017951393,0.00021654548,0.0011545086,0.00004429176,0.0000797209,0.00061860564,0.000029848054],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03499607,0.0011128298,0.9528468,0.000043725875,0.00015501103,0.000091924696,0.000008802976,0.0000027741235,0.0000013316707,0.00025215987,0.00007818952,0.0104103675],"study_design_scores_gemma":[0.031931628,0.0014333464,0.95976186,0.00006431701,0.00065168017,0.0000015826031,0.0000020505931,0.000050166163,0.0000050831545,0.00056957244,0.0054340987,0.000094613126],"about_ca_topic_score_codex":0.000010860165,"about_ca_topic_score_gemma":0.0000034377617,"teacher_disagreement_score":0.014314781,"about_ca_system_score_codex":0.000022515485,"about_ca_system_score_gemma":0.00016677893,"threshold_uncertainty_score":0.4332249},"labels":[],"label_agreement":null},{"id":"W2085470371","doi":"10.1097/00002826-200307000-00007","title":"Pharmacokinetic Studies of Single and Multiple Oral Doses of Fampridine-SR (Sustained-Release 4-Aminopyridine) in Patients With Chronic Spinal Cord Injury","year":2003,"lang":"en","type":"article","venue":"Clinical Neuropharmacology","topic":"Spinal Cord Injury Research","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Lawson Health Research Institute; Western University","funders":"","keywords":"Pharmacokinetics; 4-Aminopyridine; Medicine; Dosing; Spinal cord injury; Adverse effect; Anesthesia; Oral administration; Spinal cord; Pharmacology; Internal medicine","score_opus":0.11361574447785358,"score_gpt":0.4635978927958428,"score_spread":0.34998214831798924,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2085470371","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9970224,0.0011709601,0.0000045574257,0.0002489377,0.00037568185,0.0010766967,0.000017148612,0.000023698392,0.000059945552],"genre_scores_gemma":[0.99794286,0.0010130253,0.00027169567,0.0005369298,0.00009496947,0.000022065928,0.000005350032,0.000043368116,0.00006975602],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.996841,0.0005725247,0.0011392088,0.0005658228,0.00037546258,0.000505995],"domain_scores_gemma":[0.9974926,0.0009705061,0.00034158342,0.00028213052,0.0006387455,0.00027439484],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00056211575,0.00028234627,0.0010820546,0.00031983387,0.00004009077,0.0000040830287,0.00017385869,0.000114355564,0.0001260619],"category_scores_gemma":[0.003093854,0.00022643138,0.00011211324,0.0005767537,0.0013058429,0.00007898244,0.00018649525,0.0006624729,0.000006485486],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0954061,0.0034600587,0.7656461,0.00084145175,0.00026593634,0.0002504329,0.00001215111,0.000010652986,0.11402571,0.0000265933,0.0007090901,0.019345742],"study_design_scores_gemma":[0.033592694,0.17193815,0.7238819,0.00022174162,0.00050945865,0.00002482758,0.00007444334,0.00022877108,0.06650272,0.000024197916,0.0026699295,0.0003311944],"about_ca_topic_score_codex":0.00001255678,"about_ca_topic_score_gemma":0.000005596537,"teacher_disagreement_score":0.16847809,"about_ca_system_score_codex":0.0000985935,"about_ca_system_score_gemma":0.0002870463,"threshold_uncertainty_score":0.92336035},"labels":[],"label_agreement":null},{"id":"W2085751814","doi":"10.1097/01.wnf.0000220823.80640.44","title":"Topiramate-induced Psychosis in Patients with Essential Tremor","year":2006,"lang":"en","type":"article","venue":"Clinical Neuropharmacology","topic":"Neurological disorders and treatments","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre for Movement Disorders","funders":"","keywords":"Topiramate; Paranoia; Psychosis; Psychiatry; Medicine; Essential tremor; Adverse effect; Psychology; Pediatrics; Epilepsy; Internal medicine","score_opus":0.026736962377278472,"score_gpt":0.36043257346560914,"score_spread":0.3336956110883307,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2085751814","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99514985,0.000013619201,0.0000019179433,0.0020099776,0.00056700327,0.00057741103,0.0000041009457,0.000058998387,0.0016171031],"genre_scores_gemma":[0.9914571,0.000018650884,0.00006667005,0.008026519,0.0001703263,0.000029100986,0.000018784294,0.00002365569,0.00018917191],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99832416,0.00018971387,0.00051397306,0.00050051435,0.00014795235,0.00032369187],"domain_scores_gemma":[0.99928784,0.00024227702,0.000095571755,0.00019105172,0.0000519131,0.00013136826],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00006944741,0.00017414325,0.00044475746,0.00007147741,0.0000353978,0.000007660049,0.00009005399,0.00013451512,0.0003781708],"category_scores_gemma":[0.000068483256,0.00012076681,0.00011453341,0.000198411,0.00012037688,0.000034424986,0.000039466937,0.00037487198,0.000113573646],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0028582076,0.0056725824,0.9845078,0.000010283801,0.00003356411,0.0005390728,0.0000018198784,0.0000027210485,0.0005134815,0.000033144668,0.0016591492,0.00416816],"study_design_scores_gemma":[0.017165752,0.0038515753,0.9774305,0.0000059159693,0.00011397775,0.0000025075985,6.6465424e-7,0.000029334107,0.00017322885,0.00017102074,0.00095153257,0.00010394402],"about_ca_topic_score_codex":0.000034322955,"about_ca_topic_score_gemma":0.000010802416,"teacher_disagreement_score":0.014307544,"about_ca_system_score_codex":0.000013816829,"about_ca_system_score_gemma":0.000023159662,"threshold_uncertainty_score":0.49247277},"labels":[],"label_agreement":null},{"id":"W2087320487","doi":"10.1097/00002826-200203000-00002","title":"Treatment of Patients With Tardive Dystonia With Olanzapine","year":2002,"lang":"en","type":"article","venue":"Clinical Neuropharmacology","topic":"Botulinum Toxin and Related Neurological Disorders","field":"Medicine","cited_by":37,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Spasmodic Torticollis; Cervical dystonia; Dystonia; Olanzapine; Torticollis; Rating scale; Visual analogue scale; Anesthesia; Psychology; Medicine; Schizophrenia (object-oriented programming); Surgery; Psychiatry","score_opus":0.042686683972505066,"score_gpt":0.32332059350321185,"score_spread":0.28063390953070677,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2087320487","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99472374,0.00018275839,0.000007655743,0.0024342483,0.00024751152,0.0006204596,0.0000120257355,0.00006439414,0.0017071815],"genre_scores_gemma":[0.9942474,0.0014484302,0.00019595829,0.0032886034,0.000080157006,0.00001760233,0.000011270355,0.00002861151,0.0006819867],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99849194,0.0001915237,0.00045719408,0.00041816596,0.00016823011,0.00027295662],"domain_scores_gemma":[0.9988372,0.00041293207,0.00016070463,0.0002276932,0.0001149886,0.00024650837],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000032636246,0.00020347445,0.0006165282,0.000053395142,0.00004084905,0.0000023842254,0.00008174537,0.00017041079,0.0012787807],"category_scores_gemma":[0.00005808027,0.00010664422,0.00013587867,0.0001975709,0.00055234117,0.000023577466,0.000023536282,0.0003221625,0.0001315409],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014576529,0.015673012,0.93523985,0.000052056555,0.0008830607,0.0020912045,0.00007345063,0.00005736203,0.000853711,0.000043452535,0.002321846,0.028134493],"study_design_scores_gemma":[0.033856492,0.06333369,0.86673373,0.000012739893,0.0008425883,0.00006648344,0.0000040136815,0.00044932938,0.00027899616,0.000008259654,0.034224108,0.00018959386],"about_ca_topic_score_codex":0.0000017938014,"about_ca_topic_score_gemma":5.914435e-7,"teacher_disagreement_score":0.068506114,"about_ca_system_score_codex":0.000013576769,"about_ca_system_score_gemma":0.000021020178,"threshold_uncertainty_score":0.9996342},"labels":[],"label_agreement":null},{"id":"W2087720405","doi":"10.1097/wnf.0000000000000034","title":"Liquid Melevodopa Versus Standard Levodopa in Patients With Parkinson Disease and Small Intestinal Bacterial Overgrowth","year":2014,"lang":"en","type":"article","venue":"Clinical Neuropharmacology","topic":"Gastrointestinal motility and disorders","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre for Movement Disorders; University of Toronto","funders":"","keywords":"Levodopa; Small intestinal bacterial overgrowth; Bacterial overgrowth; Medicine; Parkinson's disease; Gastroenterology; Disease; Internal medicine","score_opus":0.03021068418300843,"score_gpt":0.3101651354656374,"score_spread":0.27995445128262897,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2087720405","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9972182,0.000016781774,0.00006941539,0.0010900275,0.0007824293,0.00048148975,0.000014966257,0.000059310438,0.00026736403],"genre_scores_gemma":[0.9974052,0.000028972288,0.00070838345,0.0014846576,0.00028035732,0.000014656294,0.000028325214,0.000031036812,0.00001842848],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99773616,0.0004893509,0.0005694861,0.00061266933,0.00018870081,0.00040366547],"domain_scores_gemma":[0.9973834,0.0014957236,0.00013904466,0.0002271752,0.00013659487,0.00061803055],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004072963,0.00023980503,0.00053725205,0.00009242058,0.000051429502,0.000016030564,0.000120936405,0.000072311304,0.00019618128],"category_scores_gemma":[0.0042284406,0.00020151872,0.00008200415,0.00013928434,0.00049099734,0.000066812674,0.00013115299,0.0006010172,0.00001723088],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.23418368,0.00079397793,0.76200885,0.000059450394,0.000024253115,0.00014892749,0.000008403487,0.0000047285876,0.0001431569,0.000039910512,0.00015578643,0.0024288865],"study_design_scores_gemma":[0.028184783,0.03304593,0.93369585,0.000068711255,0.00020836695,0.000008744561,0.000005062533,0.0001549885,0.000023043562,0.00003386491,0.004418041,0.00015258495],"about_ca_topic_score_codex":0.000010444701,"about_ca_topic_score_gemma":0.000027710066,"teacher_disagreement_score":0.2059989,"about_ca_system_score_codex":0.00003417946,"about_ca_system_score_gemma":0.00014078946,"threshold_uncertainty_score":0.8217695},"labels":[],"label_agreement":null},{"id":"W2088003671","doi":"10.1097/00002826-200109000-00003","title":"Acute Spinal Cord Injury, Part II: Contemporary Pharmacotherapy","year":2001,"lang":"en","type":"review","venue":"Clinical Neuropharmacology","topic":"Spinal Cord Injury Research","field":"Medicine","cited_by":154,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; University of British Columbia","funders":"","keywords":"Medicine; Spinal cord injury; Methylprednisolone; Pharmacology; Spinal cord; Anesthesia","score_opus":0.42886155007232385,"score_gpt":0.6179216795098523,"score_spread":0.18906012943752848,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2088003671","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0022603795,0.9793838,0.0000060688108,0.0015075697,0.007943389,0.0041847443,0.00016067852,0.00032744458,0.00422588],"genre_scores_gemma":[0.00006640859,0.9666385,0.00012935995,0.01275868,0.006222571,0.0004965695,0.00018166444,0.00034612694,0.013160108],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.98958415,0.0026289634,0.0036686326,0.0020263137,0.00077752233,0.0013144272],"domain_scores_gemma":[0.9944839,0.0013840327,0.0011123331,0.0011792922,0.0003852372,0.0014552269],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0015105432,0.0011975904,0.0062456354,0.0006330832,0.0002814189,0.000042515498,0.0012751186,0.0011971003,0.00722504],"category_scores_gemma":[0.0006368954,0.0009750619,0.0025711928,0.0013522527,0.0012004753,0.00012523362,0.0008572742,0.0061647967,0.0031454733],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02560494,0.0012253653,0.00004026468,0.0025156287,0.0014625719,0.0074136006,5.5991745e-7,2.3249067e-9,0.000077222234,0.000012685929,0.22625357,0.7353936],"study_design_scores_gemma":[0.0037319774,0.063771516,0.000017452518,0.0021879505,0.0038887428,0.0016984545,8.709429e-7,0.000005204488,0.00002536454,0.000010389952,0.92401594,0.00064614264],"about_ca_topic_score_codex":0.0000054149427,"about_ca_topic_score_gemma":1.7737862e-7,"teacher_disagreement_score":0.73474747,"about_ca_system_score_codex":0.00019100406,"about_ca_system_score_gemma":0.0026961018,"threshold_uncertainty_score":0.99926996},"labels":[],"label_agreement":null},{"id":"W2094809640","doi":"10.1097/wnf.0b013e3181f0f013","title":"Quetiapine Combined With Amisulpride in Schizophrenic Patients With Insufficient Responses to Quetiapine Monotherapy","year":2010,"lang":"en","type":"article","venue":"Clinical Neuropharmacology","topic":"Schizophrenia research and treatment","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Amisulpride; Quetiapine; Olanzapine; Clozapine; Schizophrenia (object-oriented programming); Scale for the Assessment of Negative Symptoms; Positive and Negative Syndrome Scale; Medicine; Atypical antipsychotic; Internal medicine; Quetiapine Fumarate; Antipsychotic; Pharmacology; Psychology; Psychiatry; Brief Psychiatric Rating Scale; Psychosis","score_opus":0.02345249139775351,"score_gpt":0.3661104584676639,"score_spread":0.34265796706991036,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2094809640","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9880257,0.000037714104,0.000014081557,0.009377231,0.00032879724,0.0020162538,0.000013131424,0.00011139637,0.00007567586],"genre_scores_gemma":[0.99169207,0.00010713209,0.0025999802,0.004812876,0.00019561073,0.00020865888,0.000029432922,0.000077008954,0.0002772359],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9967678,0.00047256777,0.0007362472,0.00086278573,0.00047307683,0.00068750104],"domain_scores_gemma":[0.9969458,0.0011016326,0.00014011463,0.00062008144,0.00030367446,0.00088871235],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00047374616,0.00036159827,0.00077003654,0.00041344715,0.00008461857,0.000023971466,0.00028359037,0.00016721014,0.00036465586],"category_scores_gemma":[0.0008221752,0.00023713658,0.00011189011,0.00072758656,0.00044394197,0.00006015818,0.00011994279,0.001404024,0.00020678336],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.35757297,0.006149632,0.6223945,0.000019251836,0.00016452569,0.0012209123,0.000030009396,0.000015817417,0.00384087,0.00024507006,0.00035433244,0.007992115],"study_design_scores_gemma":[0.054495577,0.02679783,0.91419894,0.000040740382,0.00008559236,0.000031337364,0.0000039768533,0.00011751056,0.0014622323,0.00003315618,0.002496953,0.00023615872],"about_ca_topic_score_codex":0.000039833743,"about_ca_topic_score_gemma":0.0004328564,"teacher_disagreement_score":0.3030774,"about_ca_system_score_codex":0.000062444466,"about_ca_system_score_gemma":0.0005951541,"threshold_uncertainty_score":0.96701497},"labels":[],"label_agreement":null},{"id":"W2095110740","doi":"10.1097/wnf.0b013e31802fa61a","title":"Oral Cholinesterase Inhibitor Add-on Therapy for Cognitive Enhancement in Schizophrenia","year":2007,"lang":"en","type":"review","venue":"Clinical Neuropharmacology","topic":"Schizophrenia research and treatment","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Louis-H Lafontaine; Université du Québec à Montréal","funders":"","keywords":"Neurocognitive; Schizophrenia (object-oriented programming); Cognition; Psychology; Executive functions; Physical medicine and rehabilitation; Medicine; Psychiatry","score_opus":0.2847984843581851,"score_gpt":0.5543568871014394,"score_spread":0.26955840274325427,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2095110740","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.03967871,0.9481706,0.000013963698,0.00028138753,0.0023401557,0.009124558,0.00018693758,0.00007531587,0.00012838357],"genre_scores_gemma":[0.0011223516,0.9894961,0.00048448393,0.003559719,0.0025397986,0.0018041073,0.00044812722,0.00014850628,0.00039678047],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99427605,0.0010124723,0.0020315298,0.0013603303,0.0003806711,0.000938923],"domain_scores_gemma":[0.9905903,0.0076477006,0.00042942812,0.00040965082,0.00022263815,0.0007003253],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00115865,0.00076158834,0.0033263194,0.0006363607,0.00007794999,0.00002413467,0.00027624064,0.00067873107,0.0005643726],"category_scores_gemma":[0.0014227217,0.0005444853,0.0012487924,0.00052036357,0.00033087534,0.000040782532,0.00012515379,0.002049742,0.0005680771],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.059202757,0.0040975315,0.000071850714,0.001547756,0.0005290659,0.0022118364,0.000003799426,3.7353647e-8,0.000004931926,0.000024298673,0.0013714302,0.9309347],"study_design_scores_gemma":[0.058432665,0.014239612,0.00085868203,0.004459121,0.0012270873,0.0001131983,0.000002499405,0.000010307343,0.000098802746,0.00003185546,0.92003113,0.0004950606],"about_ca_topic_score_codex":0.000002970677,"about_ca_topic_score_gemma":0.000010226211,"teacher_disagreement_score":0.93043965,"about_ca_system_score_codex":0.00018860749,"about_ca_system_score_gemma":0.0012349527,"threshold_uncertainty_score":0.99970067},"labels":[],"label_agreement":null},{"id":"W2109594309","doi":"10.1097/01.wnf.0000236763.16032.60","title":"Plasma Homocysteine Levels and Parkinson Disease","year":2006,"lang":"en","type":"article","venue":"Clinical Neuropharmacology","topic":"Folate and B Vitamins Research","field":"Medicine","cited_by":47,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Internal medicine; Montreal Cognitive Assessment; Medicine; Homocysteine; Parkinson's disease; Depression (economics); Psychosis; Dementia; Rating scale; Beck Depression Inventory; Gastroenterology; Disease; Psychology; Psychiatry","score_opus":0.07257440747081113,"score_gpt":0.41383714245636805,"score_spread":0.3412627349855569,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2109594309","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9925741,0.00040339038,0.0000060789157,0.004673304,0.00045773486,0.0003253403,0.000017437149,0.00007011517,0.0014725197],"genre_scores_gemma":[0.991331,0.0003075929,0.000108367705,0.0027445632,0.0008708135,0.00001595702,0.000011536433,0.00002576451,0.0045844223],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983384,0.0002429648,0.0004611412,0.000438714,0.0001724076,0.0003463748],"domain_scores_gemma":[0.99847174,0.0007453088,0.000054370717,0.00020229086,0.000073034505,0.0004532646],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00028541702,0.0001363153,0.00035461545,0.000087026354,0.00007013611,0.000013570785,0.00009162844,0.00010749765,0.00042798804],"category_scores_gemma":[0.00037991116,0.00011110314,0.000111058536,0.00014475275,0.00038414053,0.000042497388,0.00012496459,0.00048167477,0.00023513983],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0055383947,0.0026971633,0.7896646,0.00027319972,0.00016536564,0.01385676,0.0000102681315,0.000008721543,0.07271487,0.00052822527,0.06380905,0.050733343],"study_design_scores_gemma":[0.00452374,0.00086794124,0.8011668,0.000009871519,0.00013182223,0.000089418114,0.0000013868059,0.0013710597,0.00070958707,0.000076820455,0.19095191,0.00009968371],"about_ca_topic_score_codex":0.0000124637745,"about_ca_topic_score_gemma":0.000002795011,"teacher_disagreement_score":0.12714286,"about_ca_system_score_codex":0.000012970182,"about_ca_system_score_gemma":0.000101053476,"threshold_uncertainty_score":0.4686169},"labels":[],"label_agreement":null},{"id":"W2329026659","doi":"10.1097/wnf.0000000000000067","title":"Effect of Midazolam on Memory During Fiberoptic Gastroscopy Under Conscious Sedation","year":2015,"lang":"en","type":"article","venue":"Clinical Neuropharmacology","topic":"Anesthesia and Sedative Agents","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Midazolam; Sedation; Anesthesia; Medicine","score_opus":0.06420667134097428,"score_gpt":0.4356038684814592,"score_spread":0.3713971971404849,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2329026659","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9972273,0.000027940992,0.000014683859,0.0007958735,0.00073660247,0.0004695015,0.0000017059456,0.000049366387,0.0006770264],"genre_scores_gemma":[0.99618876,0.000034652912,0.00006814164,0.002866339,0.00026877364,0.0000129824075,0.00000871006,0.000025801826,0.0005258456],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99779344,0.00093245466,0.0005117769,0.00033101055,0.00020035761,0.00023094034],"domain_scores_gemma":[0.99777627,0.0014283174,0.00017360055,0.00021597577,0.00010341583,0.00030240853],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00058779534,0.00015957557,0.00054534903,0.000078961326,0.000034356264,0.0000034257775,0.000101031765,0.000121920704,0.00016639568],"category_scores_gemma":[0.00070791144,0.00012465104,0.00014388117,0.00010785672,0.00030488922,0.00003463755,0.000045214274,0.00039020684,0.0003016839],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.046093147,0.0029351187,0.44787425,0.00070759427,0.00054053887,0.0034140514,0.00021503652,0.0006357946,0.47975698,0.0001099622,0.011906664,0.005810885],"study_design_scores_gemma":[0.04229973,0.044198822,0.6097384,0.00014645772,0.0011725373,0.00042829543,0.00007079088,0.0012346385,0.29910395,0.00004338233,0.001191654,0.00037135798],"about_ca_topic_score_codex":0.000001895111,"about_ca_topic_score_gemma":2.1950284e-7,"teacher_disagreement_score":0.18065304,"about_ca_system_score_codex":0.000035973877,"about_ca_system_score_gemma":0.000092518385,"threshold_uncertainty_score":0.50831217},"labels":[],"label_agreement":null},{"id":"W2330754946","doi":"10.1097/wnf.0b013e3182a5cb76","title":"Repeated Erythromycin/Codeine-Induced Psychotic Mania","year":2013,"lang":"en","type":"article","venue":"Clinical Neuropharmacology","topic":"Pharmacological Effects and Toxicity Studies","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Nova Scotia Health Authority","funders":"","keywords":"Mania; Erythromycin; Medicine; Codeine; Adverse effect; Psychiatry; Acetaminophen; Schizophrenia (object-oriented programming); Bipolar disorder; Anesthesia; Internal medicine; Antibiotics; Mood","score_opus":0.09852931102306338,"score_gpt":0.43880218417987715,"score_spread":0.34027287315681376,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2330754946","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.975595,0.00012889222,0.000015452024,0.013738492,0.0026655388,0.0013795315,0.0000030462622,0.00035171883,0.006122327],"genre_scores_gemma":[0.95492226,0.00055342965,0.00026996303,0.04173486,0.00096012105,0.00013062773,0.000004681852,0.000045440964,0.001378641],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9967483,0.0005757528,0.0009877799,0.00080636085,0.00022304534,0.0006587494],"domain_scores_gemma":[0.99693775,0.0016400144,0.0001962522,0.00036970238,0.00023142964,0.0006248606],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00040803791,0.00033328665,0.0009671551,0.00010138905,0.00015345197,0.000022750892,0.00024030141,0.00027686075,0.0045093535],"category_scores_gemma":[0.0011896058,0.00024491257,0.0003554622,0.00032727,0.00036279595,0.00009539725,0.00020331964,0.0011413579,0.0033438848],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001353944,0.0036203435,0.0317809,0.00015279789,0.00080266746,0.0024648844,0.00003501303,0.00000518318,0.74355847,0.00013620056,0.18361333,0.032476284],"study_design_scores_gemma":[0.012841285,0.007817868,0.94072276,0.000041132247,0.00082019134,0.00037378693,0.000019476736,0.0024568115,0.006944323,0.00043333182,0.026990494,0.00053853187],"about_ca_topic_score_codex":0.000019909026,"about_ca_topic_score_gemma":0.000001046793,"teacher_disagreement_score":0.90894186,"about_ca_system_score_codex":0.00003575665,"about_ca_system_score_gemma":0.0000603605,"threshold_uncertainty_score":0.99872446},"labels":[],"label_agreement":null},{"id":"W2332272503","doi":"10.1097/wnf.0b013e3181f5a5f9","title":"Bupropion for Depression in Schizophrenia","year":2010,"lang":"en","type":"article","venue":"Clinical Neuropharmacology","topic":"Schizophrenia research and treatment","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Bupropion; Positive and Negative Syndrome Scale; Psychiatry; Psychology; Extrapyramidal symptoms; Tolerability; Schizophrenia (object-oriented programming); Antidepressant; Antipsychotic; Major depressive disorder; Medicine; Psychosis; Internal medicine; Adverse effect; Mood","score_opus":0.054905050638284165,"score_gpt":0.44423502764290745,"score_spread":0.3893299770046233,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2332272503","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9941772,0.00006635312,0.00002099284,0.0028881375,0.0015678057,0.0010207613,0.0000065557133,0.000058883743,0.0001932815],"genre_scores_gemma":[0.992029,0.00012671929,0.00533784,0.0013290246,0.0007826697,0.0001934917,0.000016167665,0.000026577303,0.00015852171],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984741,0.00013369172,0.0004548894,0.00045142163,0.00012762523,0.00035823692],"domain_scores_gemma":[0.9980214,0.0012282952,0.00006167859,0.0002556676,0.000082343795,0.00035061434],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00039121235,0.00012383993,0.00035368028,0.00012560269,0.000052331645,0.000008079283,0.00012500108,0.00019125211,0.00028781168],"category_scores_gemma":[0.0014797851,0.00009813373,0.00016903655,0.0001409197,0.00016619937,0.00003740215,0.00007859779,0.00092352426,0.00014322787],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.085027054,0.0027552794,0.41546848,0.000072240735,0.000083382336,0.0011677659,0.00000886996,0.0000013831612,0.19447687,0.00086302724,0.0035207197,0.29655492],"study_design_scores_gemma":[0.030141778,0.0015658056,0.9514237,0.000013250052,0.000075134405,0.00009178639,0.0000017429596,0.0009604106,0.007668259,0.0008015715,0.007149363,0.00010720374],"about_ca_topic_score_codex":0.0000051689162,"about_ca_topic_score_gemma":0.00003638765,"teacher_disagreement_score":0.5359552,"about_ca_system_score_codex":0.00001462593,"about_ca_system_score_gemma":0.00020877585,"threshold_uncertainty_score":0.40123045},"labels":[],"label_agreement":null},{"id":"W2396912542","doi":"10.1097/wnf.0000000000000107","title":"Comparison Between Dysport and Prosigne in the Treatment of Cervical Dystonia","year":2015,"lang":"en","type":"article","venue":"Clinical Neuropharmacology","topic":"Botulinum Toxin and Related Neurological Disorders","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Cervical dystonia; Dystonia; Medicine; Dermatology; Pediatrics; Psychiatry","score_opus":0.20953117186293277,"score_gpt":0.4772698150497375,"score_spread":0.26773864318680474,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2396912542","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98961645,0.0004822672,0.0000035938192,0.008372956,0.00026484992,0.00061224966,0.0000029236226,0.000025333693,0.00061938993],"genre_scores_gemma":[0.9953458,0.0011728886,0.000057909278,0.0031713357,0.00014903492,0.000019271356,0.000005923172,0.000011269262,0.00006661897],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980506,0.00054690934,0.0007256212,0.00031384773,0.00014539986,0.00021768005],"domain_scores_gemma":[0.9983108,0.0011322653,0.00011542583,0.00017336027,0.000039766153,0.0002283737],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003805098,0.00013746733,0.0006611214,0.000048097187,0.000021818796,0.0000033484807,0.00011238414,0.00023387813,0.000038322003],"category_scores_gemma":[0.00016900925,0.00007558995,0.00010263736,0.00018706308,0.0005051902,0.000014802802,0.00003147532,0.00045916115,0.000024629331],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011111618,0.0031011843,0.98340136,0.000017629822,0.000053970114,0.0004089525,0.0002404641,0.0000064268456,0.0005870168,0.000047028727,0.001059261,0.009965558],"study_design_scores_gemma":[0.0076193507,0.013812131,0.9541191,0.0000051519432,0.00027013186,0.000043637123,0.000048813235,0.00030540215,0.0002070508,0.0001445887,0.02335179,0.00007288027],"about_ca_topic_score_codex":0.0000075026423,"about_ca_topic_score_gemma":0.0000018308272,"teacher_disagreement_score":0.029282276,"about_ca_system_score_codex":0.000012097984,"about_ca_system_score_gemma":0.000057749297,"threshold_uncertainty_score":0.30824688},"labels":[],"label_agreement":null},{"id":"W2399313480","doi":"10.1097/wnf.0000000000000102","title":"Caffeine and Progression of Parkinson Disease","year":2015,"lang":"en","type":"article","venue":"Clinical Neuropharmacology","topic":"Coffee research and impacts","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"National Center for Research Resources; National Institute of Neurological Disorders and Stroke","keywords":"Caffeine; Medicine; Parkinson's disease; Disease; Neuroscience; Psychology; Internal medicine","score_opus":0.18888405364847727,"score_gpt":0.5239963377592634,"score_spread":0.3351122841107861,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2399313480","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99303186,0.0010097806,0.0000042744973,0.0048829257,0.00030733488,0.00031991917,0.000004589948,0.000025912192,0.00041339608],"genre_scores_gemma":[0.9970512,0.00088881643,0.00012015793,0.0014107064,0.00028522473,0.0000071160375,0.0000041662515,0.000011560641,0.00022104436],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988164,0.00026997467,0.00030735432,0.00021311158,0.00018096334,0.00021224614],"domain_scores_gemma":[0.9978614,0.00045195484,0.00006780098,0.00014435183,0.00012311392,0.001351389],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00043445206,0.000076311706,0.00028971376,0.00005604121,0.000015458898,0.0000033980682,0.000056295765,0.00005114753,0.00008238589],"category_scores_gemma":[0.003426282,0.000055179342,0.000059779755,0.000099849916,0.00032275825,0.000032682725,0.00011549915,0.0002593389,0.00002464263],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012590851,0.0016675298,0.7683627,0.00021814946,0.000066350825,0.001781798,0.000032194443,9.062356e-7,0.018959757,0.00003891234,0.043946356,0.15233453],"study_design_scores_gemma":[0.0063490267,0.0051103747,0.87969804,0.000039307,0.00011711737,0.000044207514,0.000005346993,0.00069308927,0.0012593739,0.00007894022,0.10653808,0.000067113586],"about_ca_topic_score_codex":0.0000023288042,"about_ca_topic_score_gemma":2.9105263e-7,"teacher_disagreement_score":0.15226741,"about_ca_system_score_codex":0.000009135767,"about_ca_system_score_gemma":0.000264381,"threshold_uncertainty_score":0.4101827},"labels":[],"label_agreement":null},{"id":"W2405021905","doi":"10.1097/wnf.0000000000000090","title":"Tolerability and Safety of Combined Glatiramer Acetate and N-Acetylcysteine in Relapsing-Remitting Multiple Sclerosis","year":2015,"lang":"en","type":"article","venue":"Clinical Neuropharmacology","topic":"Multiple Sclerosis Research Studies","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Hôpital Charles-Le Moyne; NeuroRx Research (Canada); Jewish General Hospital","funders":"","keywords":"Tolerability; Glatiramer acetate; Multiple sclerosis; Medicine; Experimental autoimmune encephalomyelitis; Neuroprotection; Pharmacology; Neurodegeneration; Internal medicine; Adverse effect; Immunology","score_opus":0.2073606310697216,"score_gpt":0.411588515682213,"score_spread":0.2042278846124914,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2405021905","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9945555,0.00055081083,0.000012501412,0.0034143042,0.00034875143,0.0008184335,0.000011932143,0.000039560513,0.00024825396],"genre_scores_gemma":[0.99525636,0.0025359984,0.0011385196,0.00085386354,0.00009760922,0.00002335927,0.0000041783474,0.000024898327,0.00006520369],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.996627,0.0009056971,0.0012452498,0.000585546,0.0002472577,0.00038930596],"domain_scores_gemma":[0.99467564,0.0041158884,0.00022717314,0.0002694671,0.0002542749,0.00045757828],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.002184593,0.00019987169,0.0010655638,0.00011390029,0.000059543396,0.000008452049,0.00010225107,0.0001495812,0.000027858265],"category_scores_gemma":[0.01332276,0.0001715249,0.00008767176,0.00026675858,0.0012038613,0.00007674284,0.0004911972,0.0007173961,0.000005916601],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005517008,0.0005686546,0.9151203,0.0001611408,0.0000859986,0.000031545824,0.00025514586,0.000016739314,0.058303848,0.000008542885,0.00048679847,0.01944428],"study_design_scores_gemma":[0.024503456,0.001826457,0.9645306,0.00012475226,0.00007537105,0.00001210178,0.00010082898,0.0067816083,0.0010591276,0.000023561694,0.0008318408,0.00013033558],"about_ca_topic_score_codex":0.00006309284,"about_ca_topic_score_gemma":0.000023221488,"teacher_disagreement_score":0.057244718,"about_ca_system_score_codex":0.00004399811,"about_ca_system_score_gemma":0.00009367002,"threshold_uncertainty_score":0.99498844},"labels":[],"label_agreement":null},{"id":"W2802597050","doi":"10.1097/wnf.0000000000000275","title":"A Randomized Trial of Oral and Transdermal Rivastigmine for Postural Instability in Parkinson Disease Dementia","year":2018,"lang":"en","type":"article","venue":"Clinical Neuropharmacology","topic":"Parkinson's Disease and Spinal Disorders","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre for Interdisciplinary Research in Rehabilitation; Université de Montréal; Centre hospitalier universitaire de Québec; Université Laval; Children's Hospital of Eastern Ontario","funders":"","keywords":"Rivastigmine; Parkinson's disease; Transdermal; Dementia; Medicine; Postural instability; Randomized controlled trial; Disease; Physical medicine and rehabilitation; Psychology; Internal medicine; Pharmacology; Donepezil","score_opus":0.06762188235762388,"score_gpt":0.4176556982694887,"score_spread":0.3500338159118648,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2802597050","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.993331,0.00044392943,0.00006948342,0.00253983,0.0006772807,0.0027925356,0.000036053083,0.000024070374,0.000085817206],"genre_scores_gemma":[0.9961438,0.00048208935,0.0002111101,0.0027130079,0.00022110749,0.00017499329,0.000017844985,0.0000180308,0.000017992334],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9973499,0.000717071,0.0010173055,0.0004719476,0.00013432586,0.0003094187],"domain_scores_gemma":[0.9980098,0.001154756,0.00016014761,0.00017535817,0.00012120203,0.00037875294],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009971006,0.0001793203,0.0010458444,0.000100228746,0.000043466283,0.0000049345663,0.00009950902,0.00010293474,0.00010971533],"category_scores_gemma":[0.0022407484,0.00014685174,0.0003966008,0.00013702766,0.0013115482,0.000055718003,0.000047218004,0.00021474507,0.0000037956795],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.920293,0.0018289081,0.073784575,0.00012707748,0.00017478822,0.000052864398,0.000030431804,4.0116757e-7,0.0011680479,0.000042174037,0.00023025923,0.002267486],"study_design_scores_gemma":[0.611117,0.0024749467,0.37833744,0.000012897356,0.0008343528,0.0000020100258,0.000005184861,0.0014249197,0.000063154366,0.00016708011,0.0054740123,0.00008700268],"about_ca_topic_score_codex":0.0000161546,"about_ca_topic_score_gemma":0.00001380387,"teacher_disagreement_score":0.30917597,"about_ca_system_score_codex":0.000009268653,"about_ca_system_score_gemma":0.00018082336,"threshold_uncertainty_score":0.598844},"labels":[],"label_agreement":null},{"id":"W2809241434","doi":"10.1097/wnf.0000000000000285","title":"Postural Disorders and Antiparkinsonian Treatments in Parkinson Disease: An Exploratory Case-Control Study","year":2018,"lang":"en","type":"article","venue":"Clinical Neuropharmacology","topic":"Parkinson's Disease and Spinal Disorders","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Medicine; Internal medicine; Parkinson's disease; Movement disorders; Depression (economics); Levodopa; Rating scale; Logistic regression; Amantadine; Physical therapy; Disease; Psychology","score_opus":0.045309804874049044,"score_gpt":0.39931644791941845,"score_spread":0.3540066430453694,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2809241434","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99527735,0.00082659523,0.000003599186,0.001335125,0.000713197,0.0015791636,0.00004630453,0.000102734,0.000115919516],"genre_scores_gemma":[0.9921146,0.0011983775,0.000021528227,0.0059833555,0.0004442209,0.00012692517,0.00000844332,0.000053926316,0.000048591057],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9962586,0.0012590145,0.0007312997,0.0009913007,0.00020143682,0.00055832556],"domain_scores_gemma":[0.9980523,0.00034194588,0.00013307904,0.0004111942,0.000076275865,0.0009851891],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00044458537,0.00034789712,0.0006812035,0.00021231754,0.00017720221,0.000026107713,0.0001511217,0.00012710724,0.00016384412],"category_scores_gemma":[0.00030487,0.00030747885,0.0001520235,0.00028284398,0.00062741234,0.00020509632,0.0000847101,0.00043531164,0.000076027085],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007555697,0.0058541847,0.95749766,0.00002208649,0.00020399537,0.013673965,0.00025898282,9.688774e-7,0.0002611041,0.000004376165,0.00022916736,0.014437838],"study_design_scores_gemma":[0.0171274,0.008381386,0.9640057,0.000013697051,0.000765518,0.00013065926,0.0004469745,0.0011719295,0.0000036211623,0.0000472588,0.007645265,0.00026059226],"about_ca_topic_score_codex":0.000043852815,"about_ca_topic_score_gemma":0.00037926977,"teacher_disagreement_score":0.014177246,"about_ca_system_score_codex":0.000037498903,"about_ca_system_score_gemma":0.00015597932,"threshold_uncertainty_score":0.9999377},"labels":[],"label_agreement":null},{"id":"W2882844","doi":"","title":"Role of Remote Sensing in Disaster Management","year":2002,"lang":"en","type":"article","venue":"Clinical Neuropharmacology","topic":"Synthetic Aperture Radar (SAR) Applications and Techniques","field":"Engineering","cited_by":48,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Institute for Catastrophic Loss Reduction","keywords":"Remote sensing; Emergency management; Computer science; Business; Computer security; Geography; Political science","score_opus":0.024849732616658262,"score_gpt":0.304537285211696,"score_spread":0.27968755259503775,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2882844","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8919277,0.0005549499,0.046505604,0.0006824759,0.00061776466,0.00060571,0.000004586904,0.00045622958,0.058644988],"genre_scores_gemma":[0.8732998,0.0009595221,0.1251335,0.0004230513,0.000074129915,0.000001393826,5.756087e-7,0.000025414263,0.000082620805],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99913675,0.00006034576,0.00042528214,0.00017018737,0.00005252168,0.00015491016],"domain_scores_gemma":[0.9994605,0.0002546135,0.000033769258,0.00019488396,0.000011035694,0.00004515707],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00011209891,0.00008996323,0.00020271124,0.00006560567,0.00001131788,0.000002709939,0.00012180687,0.00007478141,0.00018880212],"category_scores_gemma":[0.000019458474,0.00008795014,0.00006037857,0.00013346036,0.00007782209,0.000017290573,0.00004973077,0.00020115246,0.000051855965],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000055739947,0.000048065867,0.000082749124,0.000016290778,0.00001573956,0.00002421707,0.00002693724,0.000006270134,0.0023604252,0.00015534858,0.001011336,0.99624705],"study_design_scores_gemma":[0.0006474576,0.000075067735,0.0036238139,0.000021865777,0.00004309856,0.000018317249,0.00002516939,0.21649516,0.005000163,0.0012727283,0.77260184,0.00017533876],"about_ca_topic_score_codex":0.0000020170328,"about_ca_topic_score_gemma":0.0000010535169,"teacher_disagreement_score":0.9960717,"about_ca_system_score_codex":0.000011299938,"about_ca_system_score_gemma":0.0000010115323,"threshold_uncertainty_score":0.35865024},"labels":[],"label_agreement":null},{"id":"W2920938584","doi":"10.1097/wnf.0000000000000326","title":"Real-World Experience With VMAT2 Inhibitors","year":2019,"lang":"en","type":"article","venue":"Clinical Neuropharmacology","topic":"Genetic Neurodegenerative Diseases","field":"Neuroscience","cited_by":50,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dystonia Medical Research Foundation Canada; WiLAN (Canada)","funders":"","keywords":"Tetrabenazine; Tics; Medicine; Medical prescription; Dose; Internal medicine; Vesicular monoamine transporter; Pediatrics; Psychiatry; Monoamine neurotransmitter; Pharmacology; Dopamine","score_opus":0.06645725897481558,"score_gpt":0.40164267215679794,"score_spread":0.33518541318198236,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2920938584","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98868066,0.000006726437,0.0000054591674,0.0008552852,0.0029385963,0.0006035074,0.000009945972,0.00018388024,0.006715937],"genre_scores_gemma":[0.9828491,0.00014083931,0.00010237004,0.013110116,0.0003286993,0.000063519874,0.0000010759194,0.00005585027,0.0033483955],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99623734,0.0010441545,0.00063925906,0.0012307034,0.0003216035,0.0005269347],"domain_scores_gemma":[0.9967039,0.0021166161,0.00021255625,0.0005319113,0.00006636456,0.00036864905],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0001436804,0.0002759115,0.00041128113,0.000112312,0.00011021894,0.000038857415,0.00057468814,0.00006547779,0.0020668593],"category_scores_gemma":[0.0006611196,0.0002232554,0.00013671775,0.0004872643,0.0006709407,0.00010230663,0.0002529694,0.0004719375,0.0025367432],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004545729,0.0004425045,0.11867763,0.000014107427,0.000006380754,0.0003383696,0.000048154143,0.00015732752,0.8747842,0.0006156308,0.003683107,0.0007780719],"study_design_scores_gemma":[0.0020733792,0.0011833803,0.113840416,0.0000094779225,0.00003403181,0.000025732767,0.00001586801,0.0002424553,0.8521393,0.00004291267,0.03002867,0.0003643816],"about_ca_topic_score_codex":0.0000066846983,"about_ca_topic_score_gemma":0.0000037536931,"teacher_disagreement_score":0.026345564,"about_ca_system_score_codex":0.000018474775,"about_ca_system_score_gemma":0.00010304132,"threshold_uncertainty_score":0.9988454},"labels":[],"label_agreement":null},{"id":"W2943068831","doi":"10.1097/wnf.0000000000000344","title":"Curcumin as Add-On to Antipsychotic Treatment in Patients With Chronic Schizophrenia: A Randomized, Double-Blind, Placebo-Controlled Study","year":2019,"lang":"en","type":"article","venue":"Clinical Neuropharmacology","topic":"Curcumin's Biomedical Applications","field":"Biochemistry, Genetics and Molecular Biology","cited_by":65,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Curcumin; Schizophrenia (object-oriented programming); Placebo; Antipsychotic; Positive and Negative Syndrome Scale; Medicine; Internal medicine; Adverse effect; Randomized controlled trial; Depression (economics); Psychiatry; Clinical trial; Psychology; Psychosis; Pharmacology","score_opus":0.02028843139327818,"score_gpt":0.3621573988056611,"score_spread":0.34186896741238293,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2943068831","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9860094,0.000053669923,0.000031743843,0.0005808445,0.0007216179,0.012224793,0.00001430251,0.000028317198,0.0003352718],"genre_scores_gemma":[0.9948546,0.00005684573,0.000055914014,0.0016518559,0.00038828532,0.0020918038,0.00007064198,0.000054570886,0.0007754604],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9961855,0.0008786722,0.0010011623,0.0011876943,0.00025845383,0.00048850715],"domain_scores_gemma":[0.99768263,0.0009240312,0.00024150667,0.0006925353,0.00010213259,0.0003571544],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0006157233,0.0003909506,0.0011837707,0.0001707459,0.000057237008,0.00002138049,0.0004226536,0.00023653374,0.00032201665],"category_scores_gemma":[0.0002751528,0.00027744673,0.00027848783,0.00033124347,0.00024326866,0.000004922921,0.00015435359,0.00034922495,0.0009571044],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9625195,0.006487681,0.023938842,0.000008560463,0.0004284732,0.000025983549,0.00002147328,0.00010974749,0.0039022672,0.000031954914,0.00043107057,0.0020944206],"study_design_scores_gemma":[0.95985955,0.018469416,0.015228524,0.000012705283,0.0002478314,0.0000029176927,0.000008103104,0.000065320586,0.0008728829,0.000010376554,0.0049166162,0.00030574217],"about_ca_topic_score_codex":0.000021607837,"about_ca_topic_score_gemma":0.00007171307,"teacher_disagreement_score":0.011981735,"about_ca_system_score_codex":0.00006707864,"about_ca_system_score_gemma":0.00029310732,"threshold_uncertainty_score":0.99996775},"labels":[],"label_agreement":null},{"id":"W3013161772","doi":"10.1097/wnf.0000000000000384","title":"Effect of Antidepressants on Psychotic Symptoms in Parkinson Disease: A Review of Case Reports and Case Series","year":2020,"lang":"en","type":"review","venue":"Clinical Neuropharmacology","topic":"Parkinson's Disease Mechanisms and Treatments","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; McGill University; Montreal Neurological Institute and Hospital; McGill University Health Centre; Université de Montréal","funders":"","keywords":"Venlafaxine; Mirtazapine; Mianserin; Parkinsonism; Psychosis; Psychiatry; Escitalopram; Randomized controlled trial; Medicine; Antipsychotic; Citalopram; Ziprasidone; Anticholinergic; Psychology; Antidepressant; Schizophrenia (object-oriented programming); Disease; Internal medicine; Anxiety","score_opus":0.05376582530136106,"score_gpt":0.4460727770714156,"score_spread":0.3923069517700546,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3013161772","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.078074254,0.9177726,2.3114447e-7,0.00008949985,0.0007494939,0.0030635304,0.00018516442,0.000028476368,0.000036774658],"genre_scores_gemma":[0.03100351,0.96781784,0.000016214795,0.00066707033,0.00012640664,0.00022409215,0.000046486686,0.000077466815,0.000020923973],"study_design_codex":"case_report","study_design_gemma":"not_applicable","domain_scores_codex":[0.9934382,0.0024705834,0.0024201882,0.0011269189,0.00023397618,0.00031014127],"domain_scores_gemma":[0.9950637,0.0022333176,0.0012948207,0.00063396245,0.00006292293,0.0007112757],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00082141586,0.00059646595,0.005138798,0.0001979894,0.00003212134,0.0000043582945,0.000086230975,0.00026076523,0.00011390782],"category_scores_gemma":[0.001962956,0.00043057342,0.0008878226,0.0003910089,0.00028929923,0.000038137277,0.00014310896,0.0007209472,0.0000113808555],"study_design_candidate":"case_report","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00086145906,0.00056341116,0.00116464,0.13475879,0.00036176303,0.5421366,0.000001463892,3.7218737e-8,8.1921127e-7,0.0000022147185,0.00020568116,0.31994313],"study_design_scores_gemma":[0.00343507,0.006553295,0.0005248855,0.079962336,0.017986374,0.20288539,5.1757877e-7,0.000008117873,0.000009304277,0.000006343569,0.68833053,0.00029785055],"about_ca_topic_score_codex":0.000006729384,"about_ca_topic_score_gemma":8.958197e-7,"teacher_disagreement_score":0.68812484,"about_ca_system_score_codex":0.000032783435,"about_ca_system_score_gemma":0.00028413432,"threshold_uncertainty_score":0.9998146},"labels":[],"label_agreement":null},{"id":"W3022758378","doi":"10.1097/wnf.0000000000000390","title":"Successful Treatment With Lithium in a Refractory Patient With Periodic Catatonic Features: A Case Report","year":2020,"lang":"en","type":"article","venue":"Clinical Neuropharmacology","topic":"Electroconvulsive Therapy Studies","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"MD Precision (Canada)","funders":"","keywords":"Catatonia; Electroconvulsive therapy; Lithium (medication); Refractory (planetary science); Benzodiazepine; Medicine; Antipsychotic; Atypical antipsychotic; Psychiatry; Pediatrics; Anesthesia; Schizophrenia (object-oriented programming); Internal medicine","score_opus":0.040125661092529206,"score_gpt":0.36987657790497225,"score_spread":0.32975091681244306,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3022758378","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98505855,0.0010758764,0.0000039238294,0.011966112,0.00015495854,0.0012293733,0.0000072872745,0.00010425147,0.0003996906],"genre_scores_gemma":[0.9818707,0.00089037436,0.0001734513,0.016260842,0.00026846232,0.00021006154,0.000012405459,0.000060117487,0.0002535608],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.9972748,0.00043825977,0.00074227655,0.0008689026,0.00019812267,0.00047762203],"domain_scores_gemma":[0.9980779,0.0007091942,0.00028643024,0.00033450007,0.00016225706,0.000429676],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013843228,0.00034070766,0.0009302154,0.00008173207,0.000089510155,0.000010681358,0.000094304865,0.00011852386,0.00010764973],"category_scores_gemma":[0.0002449065,0.0002153116,0.00011878889,0.00037235103,0.00048260024,0.000053173146,0.000060893784,0.00087819423,0.000027013708],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014694169,0.0014725132,0.11026798,0.0000606302,0.00046590387,0.86216545,0.0014142579,0.000005645766,0.0037561248,0.0000031221075,0.00093297113,0.0047612456],"study_design_scores_gemma":[0.051907375,0.25165907,0.107197024,0.0001545504,0.002080871,0.4440442,0.0016298483,0.00012579879,0.007736418,0.0000061058963,0.13235939,0.0010993514],"about_ca_topic_score_codex":0.0000956472,"about_ca_topic_score_gemma":0.00023751706,"teacher_disagreement_score":0.41812122,"about_ca_system_score_codex":0.00014363602,"about_ca_system_score_gemma":0.00056148315,"threshold_uncertainty_score":0.87801516},"labels":[],"label_agreement":null},{"id":"W3126282994","doi":"10.1097/wnf.0000000000000437","title":"Oral Levodopa Formulation Does Not Affect Progression of Parkinson Disease","year":2021,"lang":"en","type":"article","venue":"Clinical Neuropharmacology","topic":"Parkinson's Disease Mechanisms and Treatments","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"National Institute of Neurological Disorders and Stroke","keywords":"Levodopa; Carbidopa; Parkinson's disease; Dyskinesia; Psychology; Rating scale; Medicine; Internal medicine; Disease; Physical therapy; Developmental psychology","score_opus":0.06823438487166537,"score_gpt":0.43020540234244414,"score_spread":0.36197101747077876,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3126282994","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99632275,0.00031363618,0.000052476054,0.0012976937,0.0012717722,0.00047889372,0.000049912487,0.000066880784,0.00014596018],"genre_scores_gemma":[0.9958623,0.00050419045,0.000708334,0.0021641569,0.00025697655,0.00004169129,0.00006945472,0.000029479275,0.00036340734],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979413,0.00046738255,0.00055750227,0.00052298774,0.00024232529,0.00026849695],"domain_scores_gemma":[0.9983763,0.00048216752,0.00020201915,0.00029146846,0.00015712238,0.00049091154],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023426779,0.00017826965,0.0005158472,0.00006016282,0.00006204963,0.000007631779,0.0000765759,0.000106029394,0.00052831153],"category_scores_gemma":[0.00068346964,0.00012416992,0.00032221258,0.00015602769,0.00009976124,0.00006434053,0.00011068806,0.00023349948,0.000055840188],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0101953745,0.0067190314,0.7254369,0.00037369388,0.0003821028,0.00858781,0.00001750167,0.000008521725,0.1202448,0.00041538742,0.000964309,0.12665454],"study_design_scores_gemma":[0.0069291852,0.0011315731,0.89695936,0.00006435625,0.0008702765,0.000025238474,0.0000038810804,0.0010654207,0.061782558,0.00023119977,0.030803803,0.00013315021],"about_ca_topic_score_codex":0.0000016107766,"about_ca_topic_score_gemma":0.0000012918443,"teacher_disagreement_score":0.17152242,"about_ca_system_score_codex":0.000025052508,"about_ca_system_score_gemma":0.00022765173,"threshold_uncertainty_score":0.57846403},"labels":[],"label_agreement":null},{"id":"W3211406171","doi":"10.1097/wnf.0000000000000483","title":"Antidepressants Effects on Pain in Parkinson Disease: A Systematic Review","year":2021,"lang":"en","type":"article","venue":"Clinical Neuropharmacology","topic":"Parkinson's Disease Mechanisms and Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hotchkiss Brain Institute; Women and Children’s Health Research Institute; University of Alberta; University of Calgary","funders":"","keywords":"Placebo; Placebo response; Antidepressant; Prospective cohort study; Depression (economics)","score_opus":0.037785309027738384,"score_gpt":0.3841313402087246,"score_spread":0.34634603118098617,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3211406171","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.92109805,0.07067259,0.000016757649,0.0034786074,0.0012800092,0.0029925792,0.000024759196,0.00011783441,0.0003188134],"genre_scores_gemma":[0.9072004,0.03299577,0.00006575164,0.05879391,0.00017409169,0.0003789623,0.000033874912,0.000043045107,0.00031422536],"study_design_codex":"systematic_review","study_design_gemma":"observational","domain_scores_codex":[0.9946582,0.0031012725,0.0008673402,0.0007382196,0.0002621523,0.0003728492],"domain_scores_gemma":[0.9960512,0.0025852737,0.00018035299,0.0005260233,0.000074712014,0.0005824568],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00095071184,0.00025343476,0.00131216,0.00007716973,0.00004102784,0.000009466797,0.00012585924,0.00009653123,0.00023976619],"category_scores_gemma":[0.006398295,0.00020329283,0.00035776297,0.0003005353,0.000050736664,0.00003085426,0.00008415234,0.00040845148,0.00032822858],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0023724048,0.010813507,0.16392286,0.58677584,0.00091306947,0.20061821,0.000009581022,0.0000033898716,0.0019325751,0.00016414371,0.01123757,0.021236835],"study_design_scores_gemma":[0.018338133,0.0038790302,0.7489755,0.1879687,0.0066865957,0.00019071411,0.0000047610947,0.0008690484,0.0015983252,0.00022800038,0.030626928,0.00063423085],"about_ca_topic_score_codex":9.07872e-7,"about_ca_topic_score_gemma":7.53023e-7,"teacher_disagreement_score":0.58505267,"about_ca_system_score_codex":0.000045718905,"about_ca_system_score_gemma":0.0001848039,"threshold_uncertainty_score":0.8290041},"labels":[],"label_agreement":null},{"id":"W4214529031","doi":"10.1097/wnf.0000000000000494","title":"Clinical Management of Sleep and Sleep Disorders With Cannabis and Cannabinoids: Implications to Practicing Psychiatrists","year":2022,"lang":"en","type":"article","venue":"Clinical Neuropharmacology","topic":"Cannabis and Cannabinoid Research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Muscular Dystrophy Canada","funders":"","keywords":"Cannabidiol; Cannabis; Sleep (system call); Effects of cannabis; Zolpidem; Abstinence; Obstructive sleep apnea; Hypnotic; Endocannabinoid system","score_opus":0.02964046852465191,"score_gpt":0.4123524850349535,"score_spread":0.38271201651030157,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4214529031","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8789538,0.00042658017,0.000057747468,0.11794656,0.00047620732,0.0013886095,0.000033161406,0.000038110236,0.0006791905],"genre_scores_gemma":[0.9864856,0.0013914913,0.0009042058,0.008392757,0.00018927615,0.00048239317,0.000009813496,0.00005388857,0.002090556],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99678046,0.00060567056,0.0009824195,0.0008439849,0.00032995144,0.00045752042],"domain_scores_gemma":[0.99828386,0.00018718599,0.00025113366,0.00044317244,0.00015188885,0.00068275817],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012062172,0.00020765723,0.00062841555,0.00019264425,0.0002793614,0.000014854335,0.00021545497,0.00008248459,0.00021719265],"category_scores_gemma":[0.00021389674,0.00018401674,0.00013441348,0.0005575918,0.00056297786,0.000046845857,0.00067675865,0.0009947808,0.0000048418915],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006065227,0.0028701213,0.5826544,0.0004792056,0.0008214207,0.00033463052,0.00018107488,0.00013096911,0.0008507492,0.001020898,0.16023923,0.24435207],"study_design_scores_gemma":[0.0042106607,0.005436449,0.74789447,0.000010418754,0.0004943203,0.00015923084,0.00021670305,0.00025877843,0.000014258073,0.00006501003,0.24106492,0.00017481841],"about_ca_topic_score_codex":0.000100123536,"about_ca_topic_score_gemma":0.000046594934,"teacher_disagreement_score":0.24417725,"about_ca_system_score_codex":0.000048357128,"about_ca_system_score_gemma":0.00017913495,"threshold_uncertainty_score":0.75039846},"labels":[],"label_agreement":null},{"id":"W4248937293","doi":"10.1097/00002826-200001000-00007","title":"A Randomized Controlled Trial Comparing Pramipexole with Levodopa in Early Parkinson's Disease: Design and Methods of the CALM-PD Study","year":2000,"lang":"en","type":"article","venue":"Clinical Neuropharmacology","topic":"Parkinson's Disease Mechanisms and Treatments","field":"Medicine","cited_by":116,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"National Center for Research Resources","keywords":"Pramipexole; Levodopa; Tolerability; Parkinson's disease; Medicine; Randomized controlled trial; Entacapone; Placebo; Dopaminergic; Clinical trial; Psychology; Internal medicine; Disease; Adverse effect; Dopamine","score_opus":0.06708977375762877,"score_gpt":0.4175193602424132,"score_spread":0.35042958648478445,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4248937293","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9865687,0.00041187572,0.00022325818,0.00032137067,0.0003893382,0.011903662,0.0000029072755,0.000031443684,0.00014747446],"genre_scores_gemma":[0.9964667,0.00024710968,0.0012831218,0.00060919725,0.00010475456,0.00096188596,0.0000010133905,0.00003075177,0.00029547614],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9889458,0.008813117,0.0011110796,0.00056942925,0.00025323036,0.0003073405],"domain_scores_gemma":[0.9936435,0.005294352,0.00031829657,0.00033714095,0.000060750062,0.00034591617],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0027704937,0.0002703988,0.0025018423,0.00008573511,0.000076051205,0.000014089543,0.00016567933,0.00007995478,0.00016211208],"category_scores_gemma":[0.0010507876,0.0001470956,0.0003717759,0.00022086933,0.00045297324,0.00004113449,0.00007161401,0.00042896793,0.0000062511062],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.93258095,0.004814228,0.058054984,0.000015946895,0.0006664801,0.000569306,0.00006492803,0.000075376825,0.00007182507,0.000013302819,0.000019521227,0.0030531473],"study_design_scores_gemma":[0.789598,0.0025587636,0.2003495,0.00002817348,0.0024528543,0.000008640539,0.000009234931,0.0043486655,0.00003840059,0.00006032472,0.00044830094,0.00009913571],"about_ca_topic_score_codex":0.000029467563,"about_ca_topic_score_gemma":0.0000033973156,"teacher_disagreement_score":0.14298293,"about_ca_system_score_codex":0.000020856414,"about_ca_system_score_gemma":0.00021451851,"threshold_uncertainty_score":0.5998385},"labels":[],"label_agreement":null},{"id":"W4280488756","doi":"10.1097/wnf.0000000000000501","title":"The Effect of Rotigotine on Cognitive Function, Daytime Sleepiness, and Sleep Problems in Parkinson Disease: An Open-Label Pilot Study","year":2022,"lang":"en","type":"article","venue":"Clinical Neuropharmacology","topic":"Parkinson's Disease Mechanisms and Treatments","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Montreal Cognitive Assessment; Epworth Sleepiness Scale; Rotigotine; Parkinson's disease; Rating scale; Excessive daytime sleepiness; Medicine; Mini–Mental State Examination; Cognition; Psychology; Internal medicine; Polysomnography; Physical therapy; Sleep disorder; Cognitive impairment; Disease; Psychiatry","score_opus":0.07015290439550931,"score_gpt":0.3944054171373183,"score_spread":0.324252512741809,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4280488756","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99363214,0.0007642815,0.0000035239493,0.00042998703,0.0008224528,0.0041628536,0.000067604895,0.00003670524,0.00008044753],"genre_scores_gemma":[0.99691576,0.00019662907,0.0000044387466,0.0013891148,0.00010504188,0.001195247,0.000048107486,0.00004163111,0.00010402057],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99531996,0.0026914258,0.00064122095,0.00075375417,0.0002856014,0.0003080487],"domain_scores_gemma":[0.99702907,0.0019968934,0.00023827166,0.00030301235,0.00006739604,0.00036537682],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012497435,0.0002453774,0.00062795705,0.00009540117,0.00032271317,0.000020790621,0.00027114028,0.00002870545,0.00020018792],"category_scores_gemma":[0.0005460103,0.00017163552,0.000043338016,0.0003030477,0.00019397965,0.00006897438,0.00050732255,0.0005462362,0.000015712752],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.088974684,0.04055899,0.8309221,0.00009717314,0.00076895003,0.0011327643,0.00003705033,0.00010977355,0.0011227072,0.00005130112,0.0003310475,0.035893444],"study_design_scores_gemma":[0.039854325,0.13919052,0.8148212,0.000023289034,0.0012131922,0.000009927179,0.00002296913,0.001107786,0.000051060528,0.00006661094,0.0035131928,0.0001259272],"about_ca_topic_score_codex":0.000026613829,"about_ca_topic_score_gemma":0.0000108023705,"teacher_disagreement_score":0.09863153,"about_ca_system_score_codex":0.00003351203,"about_ca_system_score_gemma":0.00008131755,"threshold_uncertainty_score":0.6999093},"labels":[],"label_agreement":null},{"id":"W4309181475","doi":"10.1097/wnf.0000000000000528","title":"Protective Effects of Ursodeoxycholic Acid Against Oxidative Stress and Neuroinflammation Through Mitogen-Activated Protein Kinases Pathway in MPTP-Induced Parkinson Disease","year":2022,"lang":"en","type":"article","venue":"Clinical Neuropharmacology","topic":"Parkinson's Disease Mechanisms and Treatments","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"MPTP; Ursodeoxycholic acid; Oxidative stress; Pharmacology; Neuroinflammation; Superoxide dismutase; Chemistry; Endocrinology; p38 mitogen-activated protein kinases; Internal medicine; Kinase; Medicine; Dopamine; Protein kinase A; Biochemistry; Inflammation; Dopaminergic","score_opus":0.03706120007032836,"score_gpt":0.3400274841243841,"score_spread":0.30296628405405573,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4309181475","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99446493,0.00031209778,0.000022454937,0.00040019638,0.0005951041,0.0039742645,0.00012775656,0.00007149033,0.00003173104],"genre_scores_gemma":[0.9973961,0.000111270805,0.00007570032,0.0007416265,0.00009815846,0.001441907,0.00006303513,0.00005106318,0.000021154861],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9961181,0.0017193336,0.00066565257,0.0008165325,0.00031062574,0.00036971542],"domain_scores_gemma":[0.9983066,0.000554893,0.0004227859,0.00029964535,0.0000851798,0.00033093267],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00020225052,0.0003093568,0.00066903624,0.00016693056,0.00015032642,0.000009297431,0.00014513485,0.00009491949,0.00005178417],"category_scores_gemma":[0.0009600529,0.00029262577,0.00016791181,0.00040261325,0.0001625274,0.00012927885,0.00024653322,0.0007113349,0.0000057842526],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007841312,0.0039070547,0.011313628,0.0003909961,0.00020348188,0.003583983,0.00023856584,0.000019569694,0.95985395,0.0001106371,0.000015099395,0.0125217335],"study_design_scores_gemma":[0.01126555,0.0037450672,0.28030854,0.00012353742,0.00019704815,0.000010168035,0.0000520238,0.00026140743,0.70241785,0.0004557746,0.0009338951,0.000229165],"about_ca_topic_score_codex":0.000029773306,"about_ca_topic_score_gemma":0.0000034670795,"teacher_disagreement_score":0.26899493,"about_ca_system_score_codex":0.00009405328,"about_ca_system_score_gemma":0.00023979794,"threshold_uncertainty_score":0.9999526},"labels":[],"label_agreement":null},{"id":"W4323809901","doi":"10.1097/wnf.0000000000000548","title":"The Downside of Botulinum Injections for Anterocollis: A Case Series and a Review of the Literature","year":2023,"lang":"en","type":"review","venue":"Clinical Neuropharmacology","topic":"Botulinum Toxin and Related Neurological Disorders","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre for Movement Disorders","funders":"","keywords":"Medicine; Botulinum toxin; Clinical Global Impression; Weakness; Head and neck; Surgery; Abnormality; Physical therapy","score_opus":0.1151259745079861,"score_gpt":0.47201173835881644,"score_spread":0.3568857638508303,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4323809901","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0004550415,0.98908645,5.488223e-7,0.0044653486,0.00162834,0.0040905355,0.00019073309,0.00004039678,0.000042579388],"genre_scores_gemma":[0.000032087086,0.9947268,0.000019983023,0.003746668,0.00020044547,0.0003411161,0.0000116077235,0.000052929954,0.00086836814],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99587756,0.0013012275,0.0019288341,0.00048820226,0.00012645531,0.0002776931],"domain_scores_gemma":[0.9912942,0.006987826,0.0008832766,0.00048536606,0.00021606832,0.00013325765],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000788098,0.00032631803,0.0022685963,0.0000665468,0.00018791431,0.000009353933,0.00028718865,0.00059966533,0.000015321164],"category_scores_gemma":[0.0045263963,0.00014328737,0.0014125473,0.00081018364,0.0011367343,0.000022186166,0.00029234626,0.0016779851,0.0000052419214],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011536067,0.00075588695,0.000033306973,0.4462026,0.002153408,0.0035679194,0.000050818908,4.8000635e-7,0.000028237548,0.00019822754,0.07603032,0.46982518],"study_design_scores_gemma":[0.0008707278,0.0015759441,0.00002263305,0.0349641,0.004321813,0.008143102,0.000007278944,0.0000053420677,0.0000016900823,0.000068667774,0.94990504,0.000113678616],"about_ca_topic_score_codex":9.992779e-7,"about_ca_topic_score_gemma":0.0000033328151,"teacher_disagreement_score":0.8738747,"about_ca_system_score_codex":0.000008501732,"about_ca_system_score_gemma":0.00025512284,"threshold_uncertainty_score":0.72901034},"labels":[],"label_agreement":null},{"id":"W4381192770","doi":"10.1097/wnf.0000000000000557","title":"Botulinum Toxins and Zinc: From Theory to Practice—A Systematic Review","year":2023,"lang":"en","type":"article","venue":"Clinical Neuropharmacology","topic":"Botulinum Toxin and Related Neurological Disorders","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Sherbrooke","funders":"","keywords":"Botulinum toxin; Botulinum neurotoxin; Neurotoxin; Medicine; Longevity; Clinical trial; Randomized controlled trial; Meta-analysis; Zinc; Intensive care medicine; Internal medicine; Surgery; Toxin; Gerontology; Biology; Chemistry; Microbiology","score_opus":0.04423927413122207,"score_gpt":0.4346653475371222,"score_spread":0.39042607340590013,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4381192770","genre_codex":"empirical","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6965029,0.03186023,0.00021771739,0.25216866,0.006059312,0.008093319,0.00005741904,0.0014809103,0.0035594872],"genre_scores_gemma":[0.14256619,0.19355752,0.0006066537,0.6589094,0.00050525356,0.00024955886,0.000034076194,0.00010278739,0.0034686064],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99546045,0.0020300467,0.0011371674,0.0007279593,0.0002250311,0.0004193324],"domain_scores_gemma":[0.9888674,0.009785576,0.00021135453,0.00042892058,0.00010013176,0.0006066161],"candidate_categories":["metaresearch","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0015226593,0.00024514785,0.0012167454,0.00009031958,0.00008682081,0.000013454203,0.00021569655,0.00028984167,0.00046184013],"category_scores_gemma":[0.015851704,0.00017269803,0.00024487858,0.0005727207,0.00025473008,0.000055143242,0.00028462944,0.00103355,0.0032393069],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014178124,0.007629802,0.004217673,0.22695586,0.005252027,0.04191028,0.0006632642,0.000039686427,0.03956886,0.0042493655,0.6275073,0.027827755],"study_design_scores_gemma":[0.03660489,0.02844086,0.1047842,0.0679707,0.042647988,0.0027062641,0.00068704714,0.0029677323,0.0005935869,0.010997585,0.6980494,0.0035497022],"about_ca_topic_score_codex":0.0000019412696,"about_ca_topic_score_gemma":3.3935171e-7,"teacher_disagreement_score":0.5539367,"about_ca_system_score_codex":0.000010533194,"about_ca_system_score_gemma":0.000054940643,"threshold_uncertainty_score":0.9975368},"labels":[],"label_agreement":null},{"id":"W4387664863","doi":"10.1097/wnf.0000000000000574","title":"An Examination of the Relationship Between Exposure to Bisphenol A and Attention-Deficit/Hyperactivity Disorder in Children and Adolescents","year":2023,"lang":"en","type":"article","venue":"Clinical Neuropharmacology","topic":"Effects and risks of endocrine disrupting chemicals","field":"Environmental Science","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Child, Adolescent and Family Mental Health","funders":"","keywords":"CBCL; Attention deficit hyperactivity disorder; Schedule for Affective Disorders and Schizophrenia; Child Behavior Checklist; Etiology; Attention deficit; Psychology; Schizophrenia (object-oriented programming); Psychiatry; Clinical psychology; Medicine; Pediatrics","score_opus":0.029229464312136414,"score_gpt":0.3984036566485896,"score_spread":0.3691741923364532,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387664863","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9992102,0.000005830488,0.0000020185626,0.000351046,0.00007388801,0.00031708827,0.000008184478,0.000017785305,0.000013956963],"genre_scores_gemma":[0.9997667,0.000021776115,0.000021275859,0.000114585724,0.000032265372,0.000008798218,0.000004260558,0.000008869741,0.000021433269],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987533,0.00046362594,0.00026182932,0.00028835784,0.00009281872,0.00014006758],"domain_scores_gemma":[0.99870944,0.0010058022,0.00007501849,0.00012564444,0.0000049955565,0.00007908374],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00042838333,0.0000746919,0.00014449515,0.00003099083,0.00006651404,0.000006666479,0.00012790246,0.000054175507,0.000014283864],"category_scores_gemma":[0.00079637446,0.000055422544,0.000027478514,0.00027150795,0.00018676504,0.00007507872,0.00022936857,0.00022964143,0.00001885614],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000011504697,0.00010832957,0.9831719,0.0000063653206,0.0000026494035,0.0000012856258,0.000016593862,0.00006349788,0.009111085,0.0000035856383,0.000016977008,0.007486269],"study_design_scores_gemma":[0.0006646158,0.00014468077,0.99890995,0.000011386124,0.000017724738,0.0000017018489,0.000008863672,0.000104361185,0.000040243824,0.000029660341,0.000007641727,0.000059162765],"about_ca_topic_score_codex":0.00004383328,"about_ca_topic_score_gemma":0.00001400395,"teacher_disagreement_score":0.0157381,"about_ca_system_score_codex":0.000007639215,"about_ca_system_score_gemma":0.000002870263,"threshold_uncertainty_score":0.22600658},"labels":[],"label_agreement":null},{"id":"W4390322720","doi":"10.1097/wnf.0000000000000580","title":"Effect of Levodopa on Heat Hypersensitivity and Complex Motor Parkinsonism","year":2023,"lang":"en","type":"article","venue":"Clinical Neuropharmacology","topic":"Parkinson's Disease Mechanisms and Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Saskatchewan Health; Royal University Hospital; Saskatchewan Health Authority","funders":"","keywords":"Parkinsonism; Levodopa; Medicine; Asymptomatic; Atrophy; Orthostatic intolerance; Pediatrics; Movement disorders; Parkinson's disease; Physical therapy; Physical medicine and rehabilitation; Psychology; Orthostatic vital signs; Disease; Surgery; Internal medicine; Blood pressure","score_opus":0.07187846848099394,"score_gpt":0.4133951304737717,"score_spread":0.34151666199277775,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4390322720","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99688375,0.00004372958,0.000002405517,0.0008812087,0.00087385846,0.0005488032,0.000044660355,0.000120428216,0.00060118525],"genre_scores_gemma":[0.9966206,0.000443465,0.000040382114,0.0024103795,0.00019234084,0.000024748828,0.000019909552,0.000029341083,0.00021882761],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9979475,0.0007818409,0.00035540355,0.00047050114,0.00016022733,0.0002845147],"domain_scores_gemma":[0.99666595,0.0026866426,0.00006540373,0.00021396493,0.00003575157,0.00033226967],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005302878,0.00019151896,0.000683359,0.00011132426,0.00006651721,0.0000042930005,0.00005505461,0.0001072155,0.000089872294],"category_scores_gemma":[0.00048312728,0.000148685,0.00020510219,0.00016128652,0.00024547416,0.000018638388,0.00009458066,0.000260792,0.0002620225],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02758851,0.00376522,0.12940356,0.00073861884,0.0011456176,0.017189173,0.00004761526,0.000017311335,0.5550793,0.0002509264,0.010959925,0.2538142],"study_design_scores_gemma":[0.012578144,0.015988214,0.9190674,0.000033989036,0.0006744191,0.000104542814,0.000003819756,0.0035431953,0.013061072,0.000037405378,0.03475038,0.00015745692],"about_ca_topic_score_codex":0.0000067764963,"about_ca_topic_score_gemma":3.30758e-7,"teacher_disagreement_score":0.7896638,"about_ca_system_score_codex":0.000015214215,"about_ca_system_score_gemma":0.000033414875,"threshold_uncertainty_score":0.6063198},"labels":[],"label_agreement":null},{"id":"W4392691518","doi":"10.1097/wnf.0000000000000582","title":"Provider Experience With the Use of Ketamine for Refractory Status Epilepticus","year":2024,"lang":"en","type":"article","venue":"Clinical Neuropharmacology","topic":"Epilepsy research and treatment","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Ketamine; Midazolam; Propofol; Medicine; Status epilepticus; Neurointensive care; Anesthesia; Anesthetic; Epilepsy; Pharmacy; Intensive care medicine; Psychiatry; Nursing; Sedation","score_opus":0.18340622952259536,"score_gpt":0.46462725956431017,"score_spread":0.28122103004171484,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392691518","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99193215,0.0006165728,0.00015685968,0.00545111,0.0004849303,0.0011829322,0.0000324455,0.00005585268,0.00008716574],"genre_scores_gemma":[0.99334455,0.0008966838,0.00066855556,0.0024995185,0.00029156133,0.00026866375,0.000010921225,0.00003105312,0.001988516],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99847025,0.0002192961,0.000394947,0.00037640647,0.00017819466,0.00036093043],"domain_scores_gemma":[0.9933747,0.005895943,0.000062046674,0.00027100326,0.00014939455,0.00024688628],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020666163,0.00012622571,0.00032739234,0.000050609,0.00004692343,0.000017882447,0.00009172753,0.00006519069,0.00021172919],"category_scores_gemma":[0.00090189435,0.00006309088,0.00014840285,0.00015820429,0.00066058116,0.000076322496,0.000055081295,0.0003992969,0.00003324297],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.037876036,0.007807713,0.32178026,0.0019236383,0.002925491,0.0088862,0.0013931586,0.00005078999,0.09664652,0.0011712804,0.21232028,0.3072186],"study_design_scores_gemma":[0.0050078253,0.016587494,0.124054514,0.00007242544,0.00053924613,0.0000867307,0.00006118296,0.0018943369,0.003255804,0.000018892397,0.84828895,0.00013257885],"about_ca_topic_score_codex":0.000009783319,"about_ca_topic_score_gemma":0.0000039470983,"teacher_disagreement_score":0.6359687,"about_ca_system_score_codex":0.000026049793,"about_ca_system_score_gemma":0.00028609732,"threshold_uncertainty_score":0.25727716},"labels":[],"label_agreement":null},{"id":"W4413413666","doi":"10.1097/wnf.0000000000000651","title":"Assessing the Efficacy of Cognitive Enhancers in Electroconvulsive Therapy: A Randomized Controlled Trial of Rivastigmine and Memantine","year":2025,"lang":"en","type":"article","venue":"Clinical Neuropharmacology","topic":"Electroconvulsive Therapy Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Rivastigmine; Memantine; Electroconvulsive therapy; Montreal Cognitive Assessment; Cognition; Placebo; Randomized controlled trial; Medicine; Psychology; Effects of sleep deprivation on cognitive performance; Anesthesia; Internal medicine; Psychiatry; Donepezil; Dementia; Cognitive impairment","score_opus":0.03474986360129584,"score_gpt":0.4526716213914023,"score_spread":0.4179217577901065,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413413666","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9834671,0.0034850377,0.00007224376,0.0038052713,0.0004762441,0.008015852,0.0000011125023,0.000017762532,0.000659367],"genre_scores_gemma":[0.9871738,0.009131009,0.000029267625,0.0029105223,0.00016285141,0.00043906408,0.0000018102584,0.000017071934,0.00013458032],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99449825,0.002800108,0.0018498474,0.00039267936,0.00016079514,0.00029833624],"domain_scores_gemma":[0.9439089,0.054735936,0.0007677637,0.00016359746,0.00037023882,0.000053594278],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0026306044,0.00023812856,0.0034163378,0.00023137871,0.000053654407,0.0000065578092,0.00013737615,0.00011890311,0.00004839838],"category_scores_gemma":[0.014779943,0.00014038055,0.0004994313,0.00043329975,0.0017630999,0.0000398067,0.00008058225,0.0006468295,8.111738e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.88440245,0.001186306,0.0013959764,0.000038396476,0.0017240307,0.000025438814,0.00014107762,5.2475036e-7,0.10643464,0.00010260139,0.000043138138,0.004505384],"study_design_scores_gemma":[0.9495723,0.0031202054,0.012154266,0.00015353534,0.0011715671,0.000005527083,0.00007182025,0.00013942384,0.033358935,0.00013707828,0.000032431646,0.00008288023],"about_ca_topic_score_codex":0.00000835838,"about_ca_topic_score_gemma":0.0000019931722,"teacher_disagreement_score":0.07307571,"about_ca_system_score_codex":0.000015639635,"about_ca_system_score_gemma":0.00030524374,"threshold_uncertainty_score":0.993519},"labels":[],"label_agreement":null},{"id":"W4417049185","doi":"10.1097/wnf.0000000000000665","title":"Amitriptyline for Refractory Idiopathic Intractable Hiccups: A Case Report","year":2025,"lang":"en","type":"article","venue":"Clinical Neuropharmacology","topic":"Pathogenesis and Treatment of Hiccups","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Government of New Brunswick","funders":"","keywords":"Amitriptyline; Refractory (planetary science); Intractable epilepsy; Psychogenic disease; Gabapentin; Mood","score_opus":0.07417162951320497,"score_gpt":0.4633633643222183,"score_spread":0.38919173480901337,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417049185","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9864787,0.001982607,0.00046436378,0.004401819,0.003565845,0.0011473096,0.000027940547,0.00016231035,0.0017691439],"genre_scores_gemma":[0.9823263,0.00060115126,0.0009215629,0.0095826965,0.000991905,0.00019705837,0.000034421133,0.000038214814,0.005306679],"study_design_codex":"case_report","study_design_gemma":"not_applicable","domain_scores_codex":[0.9971356,0.00028760586,0.0012771605,0.00075304334,0.000124082,0.00042250604],"domain_scores_gemma":[0.9971022,0.0015504169,0.00028521067,0.0005140328,0.0002732397,0.0002749217],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011279586,0.00024616063,0.0008649731,0.00016577732,0.00016037817,0.0000126992,0.00011834073,0.0003018489,0.000105982544],"category_scores_gemma":[0.00330429,0.00020603277,0.00043094307,0.0002591027,0.00021603335,0.000056604877,0.00009684757,0.0005767704,0.000045258068],"study_design_candidate":"case_report","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006465451,0.0076061888,0.038543005,0.0005111899,0.0009639593,0.78810215,0.000015138217,0.000007330603,0.058565434,0.0006587747,0.049347132,0.049214225],"study_design_scores_gemma":[0.03745915,0.0093389405,0.03282795,0.00024207243,0.0059997356,0.116388105,0.00006691057,0.0023096588,0.017164636,0.0006795575,0.7767844,0.0007388856],"about_ca_topic_score_codex":0.000007695027,"about_ca_topic_score_gemma":0.000003283676,"teacher_disagreement_score":0.72743726,"about_ca_system_score_codex":0.00006009894,"about_ca_system_score_gemma":0.0004967895,"threshold_uncertainty_score":0.84017724},"labels":[],"label_agreement":null},{"id":"W44850464","doi":"10.1097/wnf.0b013e3180340319","title":"The Effect of Duloxetine on Primary Pain Symptoms in Parkinson Disease","year":2007,"lang":"en","type":"article","venue":"Clinical Neuropharmacology","topic":"Parkinson's Disease Mechanisms and Treatments","field":"Medicine","cited_by":106,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Duloxetine; McGill Pain Questionnaire; Duloxetine Hydrochloride; Visual analogue scale; Parkinson's disease; Brief Pain Inventory; Rating scale; Medicine; Quality of life (healthcare); Physical therapy; Psychology; Disease; Chronic pain; Internal medicine","score_opus":0.017901058865947807,"score_gpt":0.3595551155893931,"score_spread":0.34165405672344534,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W44850464","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99617577,0.00050473044,0.000018709996,0.0009276471,0.00085263234,0.0007862392,0.000009434797,0.000040426916,0.0006844063],"genre_scores_gemma":[0.9946571,0.00042546008,0.00002042024,0.0044011297,0.0002525718,0.00004447092,0.000013382043,0.000029144408,0.00015634537],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9970041,0.0012085976,0.00071084214,0.00043270233,0.00023303625,0.00041073398],"domain_scores_gemma":[0.9915413,0.0074612363,0.00017177941,0.00032740494,0.000032446434,0.00046578504],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0028396412,0.00020369119,0.000514639,0.00009736409,0.00006484535,0.0000044211997,0.00015221965,0.00009997333,0.00006277947],"category_scores_gemma":[0.0016836612,0.0001259765,0.0002591148,0.00019892678,0.0002334065,0.000017337585,0.00006928278,0.00041481407,0.000057414407],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.027428871,0.0014546649,0.7730198,0.00010683904,0.0001346035,0.004086127,0.000004220762,0.000005173689,0.0016251926,0.00006637988,0.00086795544,0.19120018],"study_design_scores_gemma":[0.009134442,0.0061133713,0.91361547,0.000045357483,0.00025739038,0.000004849184,0.0000011870288,0.00017882687,0.0014293803,0.000038729147,0.0690912,0.000089806934],"about_ca_topic_score_codex":0.0000030021167,"about_ca_topic_score_gemma":0.0000018369208,"teacher_disagreement_score":0.19111037,"about_ca_system_score_codex":0.00005336654,"about_ca_system_score_gemma":0.00007368058,"threshold_uncertainty_score":0.51371723},"labels":[],"label_agreement":null}]}